1
|
Fabritz L, Chua W, Cardoso VR, Al-Taie C, Borof K, Suling A, Krause L, Kany S, Magnussen C, Wegscheider K, Breithardt G, Crijns HJGM, Camm AJ, Gkoutos G, Ellinor PT, Goette A, Schotten U, Wienhues-Thelen UH, Zeller T, Schnabel RB, Zapf A, Kirchhof P. Blood-based cardiometabolic phenotypes in atrial fibrillation and their associated risk: EAST-AFNET 4 biomolecule study. Cardiovasc Res 2024:cvae067. [PMID: 38613511 DOI: 10.1093/cvr/cvae067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2024] [Revised: 03/27/2024] [Accepted: 04/02/2024] [Indexed: 04/15/2024] Open
Abstract
BACKGROUND Atrial fibrillation (AF) and concomitant cardiometabolic disease processes interact and combine to lead to adverse events such as stroke, heart failure, myocardial infarction, and cardiovascular death. Circulating biomolecules provide quantifiable proxies for cardiometabolic disease processes. Their role in defining subphenotypes of AF is not known. METHODS AND RESULTS This prespecified analysis of the EAST-AFNET4 biomolecule study assigned patients to clusters using polytomous variable latent class analysis (poLCA) based on baseline concentrations of thirteen precisely-quantified biomolecules potentially reflecting ageing, cardiac fibrosis, metabolic dysfunction, oxidative stress, cardiac load, endothelial dysfunction, and inflammation. In each cluster, rates of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome, the primary outcome of EAST-AFNET 4, were calculated and compared between clusters over median 5.1 years follow-up. Findings were independently validated in a prospective cohort of 748 patients with AF (BBC-AF; median follow up 2.9 years).Unsupervised biomolecule analysis assigned 1586 patients (71 years old, 46% women) into four clusters. The highest-risk cluster was dominated by elevated BMP10, IGFBP7, NT-proBNP, ANGPT2 and GDF15. Patients in the lowest-risk cluster showed low concentrations of these biomolecules. Two intermediate-risk clusters differed by high or low concentrations of hsCRP, IL-6, and D-dimer. Patients in the highest-risk cluster had a 5-fold higher cardiovascular event rate than patients in the low-risk cluster. Early rhythm control was effective across clusters (pinteraction = 0.63). Sensitivity analyses and external validation in BBC-AF replicated clusters and risk gradients. CONCLUSIONS Biomolecule concentrations identify cardiometabolic subphenotypes in patients with atrial fibrillation at high and low cardiovascular risk.
Collapse
Affiliation(s)
- Larissa Fabritz
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany
- AFNET, Münster, Germany
- Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom
| | - Winnie Chua
- Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom
| | - Victor R Cardoso
- Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom
| | - Christoph Al-Taie
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany
| | - Katrin Borof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Linda Krause
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Shino Kany
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Christina Magnussen
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany
- Center for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | | | - Harry J G M Crijns
- Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
| | - A John Camm
- Clinical Sciences, St George´s University, London, UK
| | - George Gkoutos
- Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom
| | - Patrick T Ellinor
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
| | | | - Ulrich Schotten
- AFNET, Münster, Germany
- Department of Physiology, Maastricht University, Maastricht, The Netherlands
| | | | - Tanja Zeller
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany
| | - Renate B Schnabel
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany
| | - Antonia Zapf
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- AFNET, Münster, Germany
- Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom
| |
Collapse
|
2
|
Cordes D, Gerloff C, Heise KF, Hummel FC, Schulz R, Wolf S, Haevernick K, Krüger H, Krause L, Suling A, Wegscheider K, Zapf A, Dressnandt J, Schäpers B, Schrödl C, Hauptmann B, Kirchner A, Brault A, Gutschalk A, Richter C, Nowak DA, Veldema J, Koch G, Maiella M, Dohle C, Jettkowski K, Pilz M, Hamzei F, Olischer L, Renner C, Groß M, Jöbges M, Voller B. Efficacy and safety of transcranial direct current stimulation to the ipsilesional motor cortex in subacute stroke (NETS): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Reg Health Eur 2024; 38:100825. [PMID: 38476746 PMCID: PMC10928272 DOI: 10.1016/j.lanepe.2023.100825] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 12/02/2023] [Accepted: 12/07/2023] [Indexed: 03/14/2024]
Abstract
Background Each year, five million people are left disabled after stroke. Upper-extremity (UE) dysfunction is a leading problem. Neuroplasticity can be enhanced by non-invasive brain stimulation (NIBS) but evidence from large, randomized multicenter trials is lacking. We aimed at demonstrating efficacy of NIBS to enhance motor recovery after ischemic stroke. Methods We randomly assigned patients to receive anodal transcranial direct current (tDCS, 1 mA, 20 min) or placebo stimulation ('control') over the primary motor cortex of the lesioned hemisphere in addition to standardized rehabilitative training over ten days in the subacute phase after stroke. The original study was planned to enrol 250 but, following a blinded interim analysis, ended with 123 participants. The primary outcome parameter was UE impairment, measured by UE-Fugl-Meyer-Assessment (UEFMA), one to seven days after the end of the treatment intervention (ClinicalTrials.gov, NCT00909714). Findings From 2009 to 2019, 123 patients were included, with 119 entering intention-to-treat analysis (ITT). The control group (N = 61) improved 8.9 (SD 7.7) UEFMA points, the tDCS group (N = 58) improved 9.0 (8.8) points. ITT was neutral with respect to the primary efficacy endpoint (p = 0.820). We found no difference in UEFMA change between active tDCS and control. The safety profile of tDCS was favorable. In particular, there were no seizures. Interpretation In patients with ischemic stroke, anodal tDCS applied to the motor cortex of the lesioned hemisphere over 10 days in the subacute phase was safe but did not improve the recovery of upper extremity function compared with placebo stimulation. Funding Deutsche Forschungsgemeinschaft (GE 844/4-1).
Collapse
|
3
|
Waldmann T, Schaible J, Stiawa M, Becker T, Wegscheider K, Adema B, Wiegand-Grefe S, Kilian R. The cost-utility of an intervention for children and adolescents with a parent having a mental illness in the framework of the German health and social care system: a health economic evaluation of a randomized controlled trial. Child Adolesc Psychiatry Ment Health 2023; 17:141. [PMID: 38129868 PMCID: PMC10740235 DOI: 10.1186/s13034-023-00693-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 12/12/2023] [Indexed: 12/23/2023] Open
Abstract
BACKGROUND Children of families with a parent with a mental illness have an increased risk of developing social and mental health problems resulting in decreased quality of life. Therefore, children and adolescents living in families with a parent with mental illness are regarded as a target group for preventive interventions. To date, only a few economic evaluation studies for interventions directed at preventing the intergenerational transmission of mental health problems exist. In this investigation we estimated the cost utility of an intervention for the support of children and adolescents with a parent having a mental illness from the perspective of the German health and social care system. METHODS We randomly assigned a total of 214 families with 337 children and adolescents to the intervention (INT) group (108/170) or the control (TAU) group (106/167). Families in the intervention group received on average eight intervention sessions (50-90 min) over 6 months. We estimated total cost of illness by means of the Children and Adolescent Mental Health Service Receipt Inventory (CAMHSRI) over 24 months. For the estimation of Quality-Adjusted Live Years (QALYs) we applied the KIDSCREEN-10. For estimating the incremental cost-utility of the intervention compared to treatment as usual we used the net-benefit approach. RESULTS We estimated the annual cost of illness amounting to € 3784.59 (SD € 8581.11) in the TAU group and € 3264.44 (SD € 9431.89) in the INT group. The annual cost difference between INT and TAU was € - 516.14 (SE 1124.95) which was not significant (p ≤ 0.05). We estimated the average QALY to be 0.759 (SD 0.073) in the TAU group and 0.763 (SD 0.072). The QALY difference between INT and TAU was 0.0037 (SE 0.0092) which was not significant (p ≤ 0.05). The incremental cost utility ratio (ICUR) indicated that the gain of one additional year in full health by means of the intervention was associated with the saving of € 139.49. However, the stochastic insecurity of the ICUR did not allow a unique decision about the cost-utility of the intervention. CONCLUSIONS More information on the economic value of the intervention for families with a parent with mental illness in comparison to treatment as usual in Germany is needed. TRIAL REGISTRATION ClinicalTrials.gov, identifier NCT02308462; German Clinical Trials Register: DRKS00006806.
Collapse
Affiliation(s)
- Tamara Waldmann
- Department of Psychiatry and Psychotherapy at BKH Günzburg II, Ulm University, Lindenallee 2, 89312, Günzburg, Germany
| | - Jochen Schaible
- Department of Psychiatry and Psychotherapy at BKH Günzburg II, Ulm University, Lindenallee 2, 89312, Günzburg, Germany
- Abteilung für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, ZfP Südwürttemberg, Ravensburg, Germany
| | - Maja Stiawa
- Department of Psychiatry and Psychotherapy at BKH Günzburg II, Ulm University, Lindenallee 2, 89312, Günzburg, Germany
| | - Thomas Becker
- Department of Psychiatry and Psychotherapy at BKH Günzburg II, Ulm University, Lindenallee 2, 89312, Günzburg, Germany
- Universitätsklinikum Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Leipzig, Germany
| | - Karl Wegscheider
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Bonnie Adema
- Department for Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Silke Wiegand-Grefe
- Department for Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Reinhold Kilian
- Department of Psychiatry and Psychotherapy at BKH Günzburg II, Ulm University, Lindenallee 2, 89312, Günzburg, Germany.
| |
Collapse
|
4
|
Butter C, Klein G, Grönefeld G, Böcker D, Suling A, Buchholz A, Felk A, Hauser T, Wegscheider K, Bänsch D. Relationship between ICD implantation volume and treatment parameters of patients receiving an ICD with remote monitoring. Technol Health Care 2023:THC230641. [PMID: 37955096 DOI: 10.3233/thc-230641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023]
Abstract
BACKGROUND Both highly specialized heart centres and less specialized hospitals care for patients with implantable ICDs/CRT-Ds with remote monitoring. OBJECTIVE To investigate potential differences in patient treatment according to centre's ICD implantation volume. METHODS Based on their 2012 ICD/CRT-D implantation volume, centres enrolled in the NORDIC ICD trial in Germany were assigned to one of three groups: high- (HV, n= 345), medium- (MV, n= 340) or low-volume (LV, n= 189). RESULTS The HV-centres had a significant higher CRT-D proportion (41.7%; LV: 36.5%; MV: 23.2%; P𝑔𝑙𝑜𝑏𝑎𝑙< 0.001), significant shorter median procedure duration (49 min; MV: 58 min; LV: 60 min; P𝑔𝑙𝑜𝑏𝑎𝑙< 0.001) but significant longer median hospital stay (4 days; MV and LV: 3 days; P𝑔𝑙𝑜𝑏𝑎𝑙< 0.001) compared to MV- and LV-centres. The X-ray exposure was shorter in MV/HV-centres (MV: 3.4 min; HV: 3.6 min; LV: 5.5 min; P𝑔𝑙𝑜𝑏𝑎𝑙< 0.001). Only 3.5% (LV: 2.6%; HV: 3.5%; MV: 4.1%) patients received at least one delivered inappropriate shock and 2.5% (HV: 2.0%; LV: 2.6%; MV: 2.9%) patients had withheld inappropriate ICD shocks without subsequent inappropriate shock delivery within 24.5 months of median follow-up. CONCLUSION Implantation volume-dependent differences were observed in the device selection, procedure duration and x-ray exposure duration. Remote monitoring in combination with adequate response pattern prevented imminent inappropriate shocks in all three groups.
Collapse
Affiliation(s)
- Christian Butter
- Department of Cardiology, Heart Centre Brandenburg Bernau & Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Bernau, Germany
| | - Gunnar Klein
- Heart Center Hannover, Clinic for Cardiology & Electrophysiology, Hannover, Germany
| | | | - Dirk Böcker
- Department of Cardiology, St. Marien Hospital, Hamm, Germany
| | - Anna Suling
- University Medical Center Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany
| | - Anika Buchholz
- University Medical Center Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany
| | | | | | - Karl Wegscheider
- University Medical Center Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany
| | - Dietmar Bänsch
- KMG Clinic, Department of Rhythmology and Clinical Electrophysiology, Güstrow, Germany
| |
Collapse
|
5
|
Kany S, Al-Taie C, Roselli C, Pirruccello JP, Borof K, Reinbold C, Suling A, Krause L, Reissmann B, Schnabel RB, Zeller T, Zapf A, Wegscheider K, Fabritz L, Ellinor PT, Kirchhof P. Association of genetic risk and outcomes in patients with atrial fibrillation: interactions with early rhythm control in the EAST-AFNET4 trial. Cardiovasc Res 2023; 119:1799-1810. [PMID: 37264683 PMCID: PMC10405565 DOI: 10.1093/cvr/cvad027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 12/23/2022] [Accepted: 01/09/2023] [Indexed: 06/03/2023] Open
Abstract
AIMS The randomized Early Treatment of Atrial Fibrillation for Stroke Prevention Trial found that early rhythm control reduces cardiovascular events in patients with recently diagnosed atrial fibrillation (AF) compared with usual care. How genetic predisposition to AF and stroke interacts with early rhythm-control therapy is not known. METHODS AND RESULTS Array genotyping and imputation for common genetic variants were performed. Polygenic risk scores (PRS) were calculated for AF (PRS-AF) and ischaemic stroke risk (PRS-stroke). The effects of PRS-AF and PRS-stroke on the primary outcome (composite of cardiovascular death, stroke, and hospitalization for acute coronary syndrome or worsening heart failure), its components, and recurrent AF were determined.A total of 1567 of the 2789 trial patients were analysed [793 randomized to early rhythm control; 774 to usual care, median age 71 years (65-75), 704 (44%) women]. Baseline characteristics were similar between randomized groups. Early rhythm control reduced the primary outcome compared with usual care [HR 0.67, 95% CI: (0.53, 0.84), P < 0.001]. The randomized intervention, early rhythm control, did not interact with PRS-AF (interaction P = 0.806) or PRS-stroke (interaction P = 0.765). PRS-AF was associated with recurrent AF [HR 1.08 (01.0, 1.16), P = 0.047]. PRS-stroke showed an association with the primary outcome [HR 1.13 (1.0, 1.27), P = 0.048], driven by more heart failure events [HR 1.23 (1.05-1.43), P = 0.010] without differences in stroke [HR 1.0 (0.75, 1.34), P = 0.973] in this well-anticoagulated cohort. In a replication analysis, PRS-stroke was associated with incident AF [HR 1.16 (1.14, 1.67), P < 0.001] and with incident heart failure in the UK Biobank [HR 1.08 (1.06, 1.10), P < 0.001]. The association with heart failure was weakened when excluding AF patients [HR 1.03 (1.01, 1.05), P = 0.001]. CONCLUSIONS Early rhythm control is effective across the spectrum of genetic AF and stroke risk. The association between genetic stroke risk and heart failure calls for research to understand the interactions between polygenic risk and treatment. REGISTRATION ISRCTN04708680, NCT01288352, EudraCT2010-021258-20, www.easttrial.org.
Collapse
Affiliation(s)
- Shinwan Kany
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Christoph Al-Taie
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
| | - Carolina Roselli
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - James P Pirruccello
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
- Division of Cardiology, University of California San Francisco, San Francisco, CA, USA
| | - Katrin Borof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Carla Reinbold
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Linda Krause
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Bruno Reissmann
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
| | - Renate B Schnabel
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
| | - Tanja Zeller
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
| | - Antonia Zapf
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
| | - Larissa Fabritz
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
- Institute of Cardiovascular Sciences, University of Birmingham, Wolfson Drive, Birmingham, UK
| | - Patrick T Ellinor
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20248 Hamburg, Germany
- University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/Lübeck, Germany
- Institute of Cardiovascular Sciences, University of Birmingham, Wolfson Drive, Birmingham, UK
| |
Collapse
|
6
|
Gottschalk S, Kany S, König HH, Crijns HJGM, Vardas P, Camm AJ, Wegscheider K, Metzner A, Rillig A, Kirchhof P, Dams J. Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial. Europace 2023; 25:euad051. [PMID: 36966734 PMCID: PMC10227663 DOI: 10.1093/europace/euad051] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 01/30/2023] [Indexed: 03/29/2023] Open
Abstract
AIMS The randomized, controlled EAST-AFNET 4 trial showed that early rhythm control (ERC) reduces the rate of a composite primary outcome (cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome) by ∼20%. The current study examined the cost-effectiveness of ERC compared to usual care. METHODS AND RESULTS This within-trial cost-effectiveness analysis was based on data from the German subsample of the EAST-AFNET 4 trial (n = 1664/2789 patients). Over a 6-year time horizon and from a healthcare payer's perspective, ERC was compared to usual care regarding costs (hospitalization and medication) and effects (time to primary outcome; years survived). Incremental cost-effectiveness ratios (ICERs) were calculated. Cost-effectiveness acceptability curves were constructed to visualize uncertainty. Early rhythm control was associated with higher costs [+€1924, 95% CI (-€399, €4246)], resulting in ICERs of €10 638 per additional year without a primary outcome and €22 536 per life year gained. The probability of ERC being cost-effective compared to usual care was ≥95% or ≥80% at a willingness-to-pay value of ≥€55 000 per additional year without a primary outcome or life year gained, respectively. CONCLUSION From a German healthcare payer's perspective, health benefits of ERC may come at reasonable costs as indicated by the ICER point estimates. Taking statistical uncertainty into account, cost-effectiveness of ERC is highly probable at a willingness-to-pay value of ≥€55 000 per additional life year or year without a primary outcome. Future studies examining the cost-effectiveness of ERC in other countries, subgroups with higher benefit from rhythm control therapy, or cost-effectiveness of different modes of ERC are warranted.
Collapse
Affiliation(s)
- Sophie Gottschalk
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Martinistraße 52 Building W37, 20246 Hamburg, Germany
| | - Shinwan Kany
- Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany
| | - Hans-Helmut König
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Martinistraße 52 Building W37, 20246 Hamburg, Germany
| | - Harry JGM Crijns
- Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM), Universiteitssingel 50, 6200 MD, Maastricht, The Netherlands
| | - Panos Vardas
- European Society of Cardiology Health Policy Unit, European Heart Health Institute, European Heart Agency, 29 square de Meeus, B-1000 Brussels, BELGIUM
| | - A John Camm
- Molecular & Clinical Sciences Research Institute, St George's University of London, Cranmer Terrace, London SW17 0RE, UK
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Christoph-Probst-Weg 1, 20246 Hamburg, Germany
| | - Andreas Metzner
- Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany
| | - Andreas Rillig
- Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center Hamburg-Eppendorf, Martinistraße 52, Hamburg 20246, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany
- College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - Judith Dams
- Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg Center for Health Economics, Martinistraße 52 Building W37, 20246 Hamburg, Germany
| |
Collapse
|
7
|
Santos S, Pentzek M, Altiner A, Daubmann A, Drewelow E, Helbig C, Löffler C, Löscher S, Wegscheider K, Abholz HH, Wilm S, Wollny A. HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial. BMC Prim Care 2023; 24:115. [PMID: 37173620 PMCID: PMC10182591 DOI: 10.1186/s12875-023-02067-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 04/27/2023] [Indexed: 05/15/2023]
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is a major health problem in the western world. Despite a widespread implementation of integrated care programs there are still patients with poorly controlled T2DM. Shared goal setting within the process of Shared Decision Making (SDM) may increase patient's compliance and adherence to treatment regimen. In our secondary analysis of the cluster-randomized controlled DEBATE trial, we investigated if patients with shared vs. non-shared HbA1c treatment goal, achieve their glycemic goals. METHODS In a German primary care setting, we collected data before intervention at baseline, 6, 12 and 24 months. Patients with T2DM with an HbA1c ≥ 8.0% (64 mmol/mol) at the time of recruitment and complete data at baseline and after 24 months were eligible for the presented analyses. Using a generalized estimating equation analysis, we analysed the association between the achievement of HbA1c goals at 24 months based on their shared vs. non-shared status, age, sex, education, partner status, controlled for baseline HbA1c and insulin therapy. RESULTS From N = 833 recruited patients at baseline, n = 547 (65.7%) from 105 General Practitioners (GPs) were analysed. 53.4% patients were male, 33.1% without a partner, 64.4% had a low educational level, mean age was 64.6 (SD 10.6), 60.7% took insulin at baseline, mean baseline HbA1c was 9.1 (SD 1.0). For 287 patients (52.5%), the GPs reported to use HbA1c as a shared goal, for 260 patients (47.5%) as a non-shared goal. 235 patients (43.0%) reached the HbA1c goal after two years, 312 patients (57.0%) missed it. Multivariable analysis shows that shared vs. non-shared HbA1c goal setting, age, sex, and education are not associated with the achievement of the HbA1c goal. However, patients living without a partner show a higher risk of missing the goal (p = .003; OR 1.89; 95% CI 1.25-2.86). CONCLUSIONS Shared goal setting with T2DM patients targeting on HbA1c-levels had no significant impact on goal achievement. It may be assumed, that shared goal setting on patient-related clinical outcomes within the process of SDM has not been fully captured yet. TRIAL REGISTRATION The trial was registered at ISRCTN registry under the reference ISRCTN70713571.
Collapse
Affiliation(s)
- Sara Santos
- Institute of General Practice (ifam), Medical Faculty, Centre for Health & Society (chs), Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
| | - Michael Pentzek
- Institute of General Practice (ifam), Medical Faculty, Centre for Health & Society (chs), Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
- Institute of General Practice and Primary Care, Chair of General Practice II and Patient Centredness in Primary Care, Faculty of Health/School of Medicine, Witten/Herdecke University, Alfred-Herrhausen-Straße 50, 58448, Witten, Germany
| | - Attila Altiner
- Department of General Practice and Health Services Research, Heidelberg University Hospital, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany
- Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany
| | - Anne Daubmann
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Eva Drewelow
- Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany
| | - Christian Helbig
- Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany
| | - Christin Löffler
- Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany
| | - Susanne Löscher
- Institute of General Practice (ifam), Medical Faculty, Centre for Health & Society (chs), Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Heinz-Harald Abholz
- Institute of General Practice (ifam), Medical Faculty, Centre for Health & Society (chs), Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Stefan Wilm
- Institute of General Practice (ifam), Medical Faculty, Centre for Health & Society (chs), Heinrich Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Anja Wollny
- Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany
| |
Collapse
|
8
|
Wiegand-Grefe S, Warkentin H, Adema B, Daubmann A, Kilian R, Winter SM, Lambert M, Wegscheider K, Busmann M. Families with Mentally Ill Parents and Their Partners: Overlaps in Psychiatric Symptoms and Symptom Coping. Int J Environ Res Public Health 2023; 20:5240. [PMID: 37047856 PMCID: PMC10094103 DOI: 10.3390/ijerph20075240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 02/19/2023] [Accepted: 02/28/2023] [Indexed: 06/19/2023]
Abstract
Partners in families with a mentally ill parent often experience psychiatric symptoms themselves. Recent studies indicate that there might be overlaps in disorder-specific symptom areas between partners and spouses. This study aimed at examining associations in psychiatric symptoms and symptom coping in partners in families with a mentally ill parent, e.g., having a psychiatric diagnosis according to the International Classification of Diseases (ICD-10). Furthermore, a moderation of the psychiatric symptoms of the parent with a mental illness on the association in symptom coping was assumed. Families with at least one parent with a mental illness were recruited into the longitudinal "Children of Mentally Ill Parents" (CHIMPS) trial at seven clinical centers in Germany and Switzerland. In total, 139 families were included in the current study. Psychiatric symptoms were assessed using the Brief Symptom Inventory (BSI), Clinical Global Impression scale (CGI), Global Assessment of Functioning (GAF), and Patient Health Questionnaire (PHQ), while symptom coping strategies were measured using the Freiburger Fragebogen zur Krankheitsverarbeitung (FKV). Regression analyses have indicated an association in psychiatric symptoms between mentally ill parents and their partners concerning psychosocial functioning, somatic, and stress-related symptoms. Additionally, one symptom coping strategy of the partners was predicted by the same strategy of the parent with a mental illness. The results emphasize the importance of screening and providing support to parents burdened by the mental disorder of their partners, especially regarding the children in these partnerships.
Collapse
Affiliation(s)
- Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Hannah Warkentin
- Department of Child and Adolescent Psychiatry, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Bonnie Adema
- Department of Child and Adolescent Psychiatry, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Anne Daubmann
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Reinhold Kilian
- Department of Psychiatry and Psychotherapy II, Ulm University, 89081 Ulm, Germany
| | - Sibylle M. Winter
- Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité University Medicine Berlin, 13353 Berlin, Germany
| | - Martin Lambert
- Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Karl Wegscheider
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Mareike Busmann
- Department of Child and Adolescent Psychiatry, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| |
Collapse
|
9
|
Van Gelder IC, Ekrami NK, Borof K, Fetsch T, Magnussen C, Mulder BA, Schnabel R, Wegscheider K, Rienstra M, Kirchhof P. Sex Differences in Early Rhythm Control of Atrial Fibrillation in the EAST-AFNET 4 Trial. J Am Coll Cardiol 2023; 81:845-847. [PMID: 36813380 DOI: 10.1016/j.jacc.2022.12.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 12/08/2022] [Accepted: 12/19/2022] [Indexed: 02/22/2023]
|
10
|
Jensen M, Sehner S, Cheng B, Schlemm E, Quandt F, Barow E, Wegscheider K, Boutitie F, Ebinger M, Endres M, Fiebach JB, Thijs V, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Thomalla G, Gerloff C. Patient-Reported Quality of Life After Intravenous Alteplase for Stroke in the WAKE-UP Trial. Neurology 2023; 100:e154-e162. [PMID: 36302662 DOI: 10.1212/wnl.0000000000201375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 08/23/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Intravenous alteplase improves functional outcome after acute ischemic stroke. However, little is known about the effects on self-reported health-related quality of life (HRQoL). METHODS WAKE-UP was a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in stroke with unknown onset time. HRQoL was assessed using the EuroQol five-dimensional questionnaire (EQ-5D) at 90 days, comprising the EQ-5D index and the EQ visual analogue scale (VAS). Functional outcome was assessed by the modified Rankin Scale (mRS). We calculated the effect of treatment on EQ-5D index and EQ VAS using multiple linear regression models. Mediation analysis was performed on stroke survivors to explore the extent to which the effect of alteplase on HRQoL was mediated by functional outcome. RESULTS Among 490 stroke survivors, the EQ-5D index was available for 452 (92.2%), of whom 226 (50%) were assigned to treatment with alteplase and 226 (50%) to placebo. At 90 days, mean EQ-5D index was higher, reflecting a better health state, in patients randomized to treatment with alteplase than with placebo (0.75 vs 0.67) with an adjusted mean difference of 0.07 (95% CI 0.02-0.12, p = 0.005). In addition, mean EQ VAS was higher with alteplase than with placebo (72.6 vs 64.9), with an adjusted mean difference of 7.6 (95% CI 3.9-11.8, p < 0.001). Eighty-five percent of the total treatment effect of alteplase on the EQ-5D index was mediated using the mRS score while there was no significant direct effect. By contrast, the treatment effect on the EQ VAS was mainly through the direct pathway (60%), whereas 40% was mediated by the mRS. DISCUSSION Assessment of patient-reported outcome measures reveals a potential benefit of intravenous alteplase for HRQoL beyond improvement of functional outcome. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov number, NCT01525290; EudraCT number, 2011-005906-32.
Collapse
Affiliation(s)
- Märit Jensen
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark.
| | - Susanne Sehner
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Bastian Cheng
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Eckhard Schlemm
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Fanny Quandt
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Ewgenia Barow
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Karl Wegscheider
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Florent Boutitie
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Martin Ebinger
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Matthias Endres
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Jochen B Fiebach
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Vincent Thijs
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Robin Lemmens
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Keith W Muir
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Norbert Nighoghossian
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Salvador Pedraza
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Claus Z Simonsen
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Götz Thomalla
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| | - Christian Gerloff
- From the Klinik und Poliklinik für Neurologie (M.J., B.C., E.S., F.Q., E.B., G.T., C.G.), Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf; Institut für Medizinische Biometrie und Epidemiologie (S.S., K.W.), Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany; Hospices Civils de Lyon (F.B.), Service de Biostatistique; Université Lyon 1 (F.B.), Villeurbanne; and CNRS (F.B.), UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France; Centrum für Schlaganfallforschung Berlin (CSB) (M. Ebinger, M. Endres, J.F.) and Klinik und Hochschulambulanz für Neurologie (M. Endres), Charité-Universitätsmedizin Berlin; Neurologie (M. Ebinger), Medical Park Berlin Humboldtmühle; German Center for Neurodegenerative Disease (DZNE) (M. Endres), Partner Site Berlin; German Center for Cardiovascular Research (DZHK) (M. Endres), Partner Site Berlin; Excellence Cluster NeuroCure (M. Endres), Berlin, Germany; Florey Institute of Neuroscience and Mental Health (V.T.), University of Melbourne, Heidelberg, Victoria Department of Neurology (V.T.), Austin Health, Heidelberg, Victoria, Australia; Department of Neurology (R.L.), University Hospitals Leuven; Department of Neurosciences (R.L.), KU Leuven, University of Leuven, Experimental Neurology; VIB (R.L.), Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium; School of Psychology & Neuroscience (K.M.), University of Glasgow, United Kingdom; Department of Stroke Medicine (N.N.), Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA; Hospices Civils de Lyon (N.N.), France; Department of Radiology (S.P.), Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut dInvestigació Biomèdica de Girona (IDIBGI), Girona, Spain; and Department of Neurology (C.Z.S.), Aarhus University Hospital, Denmark
| |
Collapse
|
11
|
Jensen M, Suling A, Metzner A, Schnabel RB, Borof K, Goette A, Haeusler KG, Zapf A, Wegscheider K, Fabritz L, Diener HC, Thomalla G, Kirchhof P. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol 2023; 22:45-54. [PMID: 36517170 DOI: 10.1016/s1474-4422(22)00436-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 10/17/2022] [Accepted: 10/18/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Patients with atrial fibrillation and a history of stroke are at high risk of recurrent stroke and cardiovascular complications. In the EAST-AFNET 4 trial we showed that a systematic strategy of early rhythm control was associated with a lower risk of cardiovascular outcomes than usual care in patients with atrial fibrillation diagnosed in the past 12 months. In this pre-specified subgroup analysis we aimed to assess whether a strategy of early rhythm control is safe and can prevent adverse cardiovascular outcomes compared with usual care in such patients. METHODS EAST-AFNET 4 was a randomised, open-label trial with blinded-outcome assessment done at 135 hospitals and secondary care practices in 11 European countries. Adults with early atrial fibrillation (ie, diagnosed ≤12 months before enrolment) were randomly assigned (1:1) to either early rhythm control or usual care, with stratification according to site and variable block lengths used for concealment. The first primary outcome was time to first occurrence of the composite of cardiovascular death, ischaemic or haemorrhagic stroke, or hospital admission with worsening of heart failure or acute coronary syndrome. The second primary outcome was the number of nights spent in hospital in 1 year. The primary safety outcome was the composite of any death, stroke, or serious adverse events related to rhythm-control therapy. Here we present the results of these outcomes in patients with a history of stroke. Analyses were done in the intention-to-treat population. EAST-AFNET 4 is registered with ClinicalTrials.gov (NCT01288352), EudraCT (2010-021258-20), and ISRCTN (ISRCTN04708680). FINDINGS Between July 28, 2011, and Dec 30, 2016, 2789 patients were randomly assigned in the EAST-AFNET 4 trial to either early rhythm control (n=1395) or usual care (n=1394). Of these patients, five had no information on history of stroke and were excluded from this subgroup analysis. 217 (8%) patients had a history of stroke, of whom 110 were assigned to early rhythm control and 107 to usual care. The median age of participants with a history of stroke was 72·0 years (IQR 66·0-76·0). 95 (44%) participants were female and 122 (56%) were male. During a median follow-up of 4·7 years (3·5-6·4) for patients with a history of stroke, a first primary outcome event occurred in 18 (16%) of 110 patients in the early rhythm-control group (3·7 per 100 person-years) and 33 (31%) of 107 in the usual care group (7·4 per 100 person-years; hazard ratio [HR] 0·52, 95% CI 0·29-0·93). The mean number of nights spent in hospital per year was 5·1 (SD 13·2) for patients with a history of stroke assigned to early rhythm control and 6·6 (10·1) for those assigned to usual care (incidence rate ratio 0·87, 95% CI 0·55-1·38). Among patients with a history of stroke, primary safety events occurred in 17 (15%) patients in the early rhythm-control group versus 30 (28%) in the usual care group. INTERPRETATION In this prespecified subgroup analysis in patients with recently diagnosed atrial fibrillation and a history of stroke, the effects of early rhythm control were consistent with the findings of the primary analysis. As the evidence from this subgroup analysis is considered supportive and exploratory, further research is needed to confirm the safety and efficacy of this approach in patients with a history of stroke. FUNDING German Ministry of Education and Research, German Center for Cardiovascular Research (DZHK), Atrial Fibrillation Network (AFNET), European Heart Rhythm Association, St Jude Medical-Abbott, Sanofi, and the German Heart Foundation.
Collapse
Affiliation(s)
- Märit Jensen
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Andreas Metzner
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany
| | - Renate B Schnabel
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany; Atrial Fibrillation Network, Münster, Germany
| | - Katrin Borof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Andreas Goette
- St Vincenz Hospital Paderborn, Paderborn, Germany; Atrial Fibrillation Network, Münster, Germany
| | - Karl Georg Haeusler
- Atrial Fibrillation Network, Münster, Germany; Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany
| | - Antonia Zapf
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Atrial Fibrillation Network, Münster, Germany
| | - Larissa Fabritz
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Center of Cardiovascular Sciences, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany; Atrial Fibrillation Network, Münster, Germany; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Hans-Christoph Diener
- Institute for Medical Informatics, Biometry, and Epidemiology, University Duisburg-Essen, Essen, Germany
| | - Götz Thomalla
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany; Atrial Fibrillation Network, Münster, Germany; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
12
|
Brinkmann C, Hof H, Gysan DB, Albus C, Millentrup S, Bjarnason-Wehrens B, Latsch J, Herold G, Wegscheider K, Heming C, Seyfarth M, Predel HG. Lifestyle intervention reduces risk score for cardiovascular mortality in company employees with pre-diabetes or diabetes mellitus - A secondary analysis of the PreFord randomized controlled trial with 3 years of follow-up. Front Endocrinol (Lausanne) 2023; 14:1106334. [PMID: 36909345 PMCID: PMC9992873 DOI: 10.3389/fendo.2023.1106334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 01/30/2023] [Indexed: 02/24/2023] Open
Abstract
AIM To evaluate the effects of a multimodal intervention (including exercise training, psychosocial interventions, nutrition coaching, smoking cessation program, medical care) on the health and long-term cardiovascular disease (CVD) mortality risk of company employees with pre-diabetes or diabetes mellitus (DM) at high CVD risk. METHODS In the PreFord study, German company employees (n=4196) participated in a free-of-charge CVD mortality risk screening at their workplace. Based on their European Society of Cardiology - Systematic Coronary Risk Evaluation score (ESC-SCORE), they were subdivided into three risk groups. High-risk patients (ESC-SCORE≥5%) were randomly assigned to a 15-week lifestyle intervention or usual care control group. Data from patients with pre-DM/DM were analyzed intention-to-treat (ITT: n=110 versus n=96) and per protocol (PP: n=60 versus n=52). RESULTS Body mass index, glycated hemoglobin, total cholesterol, low-density lipoprotein, triglyceride levels as well as systolic and diastolic blood pressure improved through the intervention (ITT, PP: p<0.001). The ESC-SCORE markedly decreased from pre- to post-intervention (ITT, PP: p<0.001). ESC-SCORE changes from baseline differed significantly between the groups, with the intervention group achieving more favorable results in all follow-up visits 6, 12, 24 and 36 months later (at each time point: ITT: p<0.001; PP: p ≤ 0.010). CONCLUSION The study demonstrates the feasibility of attracting employees with pre-DM/DM at high CVD mortality risk to participate in a multimodal lifestyle program following a free CVD mortality risk screening at their workplace. The lifestyle intervention used in the PreFord study shows high potential for improving health of company employees with pre-DM/DM in the long term. ISRCTN23536103.
Collapse
Affiliation(s)
- Christian Brinkmann
- Institute of Cardiovascular Research and Sport Medicine, Department of Preventive and Rehabilitative Sport Medicine, German Sport University Cologne, Cologne, Germany
- Department of Fitness and Health, IST University of Applied Sciences, Düsseldorf, Germany
- *Correspondence: Christian Brinkmann,
| | - Hannah Hof
- Institute of Cardiovascular Research and Sport Medicine, Department of Preventive and Rehabilitative Sport Medicine, German Sport University Cologne, Cologne, Germany
| | - Detlef-Bernd Gysan
- Medical Center for Cardiology, Angiology, Pneumology and Rehabilitation Medicine, Cologne, Germany
| | - Christian Albus
- Department of Psychosomatics and Psychotherapy, University of Cologne, Cologne, Germany
| | - Stefanie Millentrup
- Institute of Cardiovascular Research and Sport Medicine, Department of Preventive and Rehabilitative Sport Medicine, German Sport University Cologne, Cologne, Germany
| | - Birna Bjarnason-Wehrens
- Institute of Cardiovascular Research and Sport Medicine, Department of Preventive and Rehabilitative Sport Medicine, German Sport University Cologne, Cologne, Germany
| | - Joachim Latsch
- Fresenius University of Applied Sciences, Cologne, Germany
| | - Gerd Herold
- Health Service of the Ford Motor Company GmbH, Cologne, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University of Hamburg-Eppendorf, Hamburg, Germany
| | - Christian Heming
- Institute of Cardiovascular Research and Sport Medicine, Department of Preventive and Rehabilitative Sport Medicine, German Sport University Cologne, Cologne, Germany
| | - Melchior Seyfarth
- HELIOS University Hospital Wuppertal, Wuppertal, Germany
- Witten/Herdecke University, Witten, Germany
| | - Hans-Georg Predel
- Institute of Cardiovascular Research and Sport Medicine, Department of Preventive and Rehabilitative Sport Medicine, German Sport University Cologne, Cologne, Germany
| |
Collapse
|
13
|
Tamisier R, Pepin J, Cowie MR, Wegscheider K, Vettorazzi E, Suling A, Angermann C, d'Ortho M, Erdmann E, Simonds AK, Somers VK, Teschler H, Lévy P, Woehrle H. Effect of adaptive servo ventilation on central sleep apnea and sleep structure in systolic heart failure patients: polysomnography data from the SERVE-HF major sub study. J Sleep Res 2022; 31:e13694. [PMID: 35840352 PMCID: PMC9787165 DOI: 10.1111/jsr.13694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 06/23/2022] [Accepted: 06/23/2022] [Indexed: 12/30/2022]
Abstract
This SERVE-HF (Treatment of Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure) sub study analysis evaluated polysomnography (PSG) data in patients with heart failure with reduced ejection fraction (HFrEF) and predominant central sleep apnea (CSA) randomised to guideline-based medical therapy, with or without adaptive servo ventilation (ASV). Patients underwent full overnight PSG at baseline and at 12 months. All PSG recordings were analysed by a core laboratory. Only data for patients with baseline and 3- or 12-month values were included. The sub study included 312 patients; the number with available PSG data differed for each variable (94-103 in the control group, 77-99 in the ASV group). After 12 months, baseline-adjusted respiratory measures were significantly better in the ASV group versus control. Although some between-group differences in sleep measures were seen at 12 months (e.g., better sleep efficiency in the ASV group), these were unlikely to be clinically significant. The number of periodic leg movements during sleep (PLMS) increased in the ASV group (p = 0.039). At 12 months, the respiratory arousal index was significantly lower in the ASV versus control group (p < 0.001), whilst the PLMS-related arousal index was significantly higher in the ASV group (p = 0.04 versus control). ASV attenuated the respiratory variables characterising sleep apnea in patients with HFrEF and predominant CSA in SERVE-HF. Sleep quality improvements during ASV therapy were small and unlikely to be clinically significant. The increase in PLMS and PLMS-related arousals during ASV warrants further investigation, particularly relating to their potential association with increased cardiovascular risk.
Collapse
Affiliation(s)
- Renaud Tamisier
- University Grenoble Alpes, Inserm, HP2 Laboratory, Pole Thorax et VaisseauxCHU Grenoble AlpesGrenobleFrance
| | - Jean‐Louis Pepin
- University Grenoble Alpes, Inserm, HP2 Laboratory, Pole Thorax et VaisseauxCHU Grenoble AlpesGrenobleFrance
| | | | - Karl Wegscheider
- Department of Medical Biometry and EpidemiologyUniversity Medical Center Hamburg‐EppendorfHamburgGermany
| | - Eik Vettorazzi
- Department of Medical Biometry and EpidemiologyUniversity Medical Center Hamburg‐EppendorfHamburgGermany
| | - Anna Suling
- Department of Medical Biometry and EpidemiologyUniversity Medical Center Hamburg‐EppendorfHamburgGermany
| | - Christiane Angermann
- Department of Medicine IUniversity and University Hospital WürzburgWürzburgGermany
| | - Marie‐Pia d'Ortho
- Hôpital Bichat, Explorations Fonctionnelles ‐ Sleep Centre, AP‐HPUniversité de ParisParisFrance
| | | | - Anita K. Simonds
- Royal Brompton and Harefield NHS Foundation Trust HospitalLondonUK
| | | | - Helmut Teschler
- Department of Pneumology, Ruhrlandklinik, West German Lung CenterUniversity Hospital Essen, University Duisburg‐EssenEssenGermany
| | | | - Holger Woehrle
- Sleep and Ventilation Center Blaubeuren, Respiratory Center UlmUlmGermany
| |
Collapse
|
14
|
Benjafield A, Woehrle H, Vettorazzi E, Wegscheider K, Simonds A, Cowie M. New treatments for central sleep apnoea in heart failure: sample size required to detect a safety signal. Sleep Med 2022. [DOI: 10.1016/j.sleep.2022.05.699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Suess H, Wiegand-Grefe S, Adema B, Daubmann A, Kilian R, Zapf A, Winter SM, Lambert M, Wegscheider K, Busmann M. Clinical Trial Data: Both Parents Having Psychiatric Symptoms as Risk Factor for Children's Mental Illness. Children (Basel) 2022; 9:1697. [PMID: 36360425 PMCID: PMC9688718 DOI: 10.3390/children9111697] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 10/30/2022] [Accepted: 11/01/2022] [Indexed: 01/07/2024]
Abstract
Children of mentally ill parents represent a particularly vulnerable risk group for the development of mental illness. This study examines whether there is a predictive association between children's psychiatric symptomatology and (1) the clinical diagnosis according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10) of their mentally ill parent as well as (2) to families both parents showing psychiatric symptoms. The study is part of the multicenter controlled trial project "Children of Mentally Ill Parents" (CHIMPS). For this purpose, the psychiatric symptomatology of the mentally ill parent (N = 196) and his or her partner (N = 134) as well as the psychiatric symptomatology of their children aged 4 to 18 years (N = 290) was measured using clinical rated ICD-10-diagnosis, self-rated Brief Symptom Inventory (BSI), and Child Behavior Checklist (CBCL). Using multilevel analyses, the severity of the parental psychiatric symptomatology (BSI) was identified as a significant predictor of children's psychiatric symptomatology (CBCL). Children of parents with a personality disorder (ICD-10) were not more affected than children of parents with another ICD-10-diagnosis. However, children with two parents showing psychiatric symptoms (CBCL) were significantly more affected than children with one mentally ill parent. The results of this study support the well-known view that parental mental illness is a risk factor for children's psychiatric symptoms. Therefore, increased support, especially in high-risk families, both parents having psychiatric symptoms, is highly necessary and should be implemented in the future psychotherapeutic family care.
Collapse
Affiliation(s)
- Hannah Suess
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Bonnie Adema
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Reinhold Kilian
- Department of Psychiatry and Psychotherapy II, Ulm University at Bezirkskrankenhaus Guenzburg, 89312 Guenzburg, Germany
| | - Antonia Zapf
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Sibylle M. Winter
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité—Universitätsmedizin Berlin, 13353 Berlin, Germany
| | - Martin Lambert
- Department of Adult Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| | - Mareike Busmann
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
| |
Collapse
|
16
|
Wolfrum S, Roedl K, Hanebutte A, Pfeifer R, Kurowski V, Riessen R, Daubmann A, Braune S, Söffker G, Bibiza-Freiwald E, Wegscheider K, Schunkert H, Thiele H, Kluge S. Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial. Circulation 2022; 146:1357-1366. [PMID: 36168956 DOI: 10.1161/circulationaha.122.060106] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
BACKGROUND This study was conducted to determine the effect of hypothermic temperature control after in-hospital cardiac arrest (IHCA) on mortality and functional outcome as compared with normothermia. METHODS An investigator initiated, open-label, blinded-outcome-assessor, multicenter, randomized controlled trial comparing hypothermic temperature control (32-34°C) for 24 h with normothermia after IHCA in 11 hospitals in Germany. The primary endpoint was all-cause mortality after 180 days. Secondary end points included in-hospital mortality and favorable functional outcome using the Cerebral Performance Category scale after 180 days. A Cerebral Performance Category score of 1 or 2 was defined as a favorable functional outcome. RESULTS A total of 1055 patients were screened for eligibility and 249 patients were randomized: 126 were assigned to hypothermic temperature control and 123 to normothermia. The mean age of the cohort was 72.6±10.4 years, 64% (152 of 236) were male, 73% (166 of 227) of cardiac arrests were witnessed, 25% (57 of 231) had an initial shockable rhythm, and time to return of spontaneous circulation was 16.4±10.5 minutes. Target temperature was reached within 4.2±2.8 hours after randomization in the hypothermic group and temperature was controlled for 48 hours at 37.0°±0.9°C in the normothermia group. Mortality by day 180 was 72.5% (87 of 120) in hypothermic temperature control arm, compared with 71.2% (84 of 118) in the normothermia group (relative risk, 1.03 [95% CI, 0.79-1.40]; P=0.822). In-hospital mortality was 62.5% (75 of 120) in the hypothermic temperature control as compared with 57.6% (68 of 118) in the normothermia group (relative risk, 1.11 [95% CI, 0.86-1.46, P=0.443). Favorable functional outcome (Cerebral Performance Category 1 or 2) by day 180 was 22.5% (27 of 120) in the hypothermic temperature control, compared with 23.7% (28 of 118) in the normothermia group (relative risk, 1.04 [95% CI, 0.78-1.44]; P=0.822). The study was prematurely terminated because of futility. CONCLUSIONS Hypothermic temperature control as compared with normothermia did not improve survival nor functional outcome at day 180 in patients presenting with coma after IHCA. The HACA in-hospital trial (Hypothermia After Cardiac Arrest in-hospital) was underpowered and may have failed to detect clinically important differences between hypothermic temperature control and normothermia. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique Identifier: NCT00457431.
Collapse
Affiliation(s)
- Sebastian Wolfrum
- Emergency Department (S.W., A.H.), University of Luebeck, Germany.,Medical Clinic II, Department of Cardiology, Angiology and Intensive Care Medicine (S.W., A.H., V.K., H.S.), University of Luebeck, Germany
| | - Kevin Roedl
- Department of Intensive Care Medicine (K.R., S.B., G.S., S.K.), University Medical Centre Hamburg-Eppendorf, Germany
| | - Alexia Hanebutte
- Emergency Department (S.W., A.H.), University of Luebeck, Germany.,Medical Clinic II, Department of Cardiology, Angiology and Intensive Care Medicine (S.W., A.H., V.K., H.S.), University of Luebeck, Germany
| | - Rüdiger Pfeifer
- Department of Internal Medicine 1, University Hospital of Jena, Germany (R.P.)
| | - Volkhard Kurowski
- Department of Intensive Care Medicine (K.R., S.B., G.S., S.K.), University Medical Centre Hamburg-Eppendorf, Germany.,Department of Cardiology and Intensive Care Medicine, DRK Hospital, Ratzeburg, Germany (V.K.)
| | - Reimer Riessen
- Department of Medicine, Medical Intensive Care Unit, University of Tübingen, Germany (R.R.)
| | - Anne Daubmann
- Institute of Medical Biometry and Epidemiology (A.D., E.B.-F.' K.W.), University Medical Centre Hamburg-Eppendorf, Germany
| | - Stephan Braune
- Department of Intensive Care Medicine (K.R., S.B., G.S., S.K.), University Medical Centre Hamburg-Eppendorf, Germany
| | - Gerold Söffker
- Department of Intensive Care Medicine (K.R., S.B., G.S., S.K.), University Medical Centre Hamburg-Eppendorf, Germany
| | - Eric Bibiza-Freiwald
- Institute of Medical Biometry and Epidemiology (A.D., E.B.-F.' K.W.), University Medical Centre Hamburg-Eppendorf, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology (A.D., E.B.-F.' K.W.), University Medical Centre Hamburg-Eppendorf, Germany.,German Centre for Cardiovascular Research (DZHK e.V.)' Partner Site Hamburg/Kiel/Lübeck' Hamburg' Germany (K.W.)
| | - Heribert Schunkert
- Medical Clinic II, Department of Cardiology, Angiology and Intensive Care Medicine (S.W., A.H., V.K., H.S.), University of Luebeck, Germany.,German Heart Center Munich, Department of Cardiology' Technical University of Munich' German Center for Cardiovascular Research (DZHK) - Munich Heart Alliance (H.S.)
| | - Holger Thiele
- Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Germany (H.T.)
| | - Stefan Kluge
- Department of Intensive Care Medicine (K.R., S.B., G.S., S.K.), University Medical Centre Hamburg-Eppendorf, Germany
| | | |
Collapse
|
17
|
Wiegand-Grefe S, Liedtke A, Morgenstern L, Hoff A, Csengoe-Norris A, Johannsen J, Denecke J, Barkmann C, Grolle B, Daubmann A, Wegscheider K, Boettcher J. Health-Related Quality of Life and mental health of families with children and adolescents affected by rare diseases and high disease burden: the perspective of affected children and their siblings. BMC Pediatr 2022; 22:596. [PMID: 36229869 PMCID: PMC9563162 DOI: 10.1186/s12887-022-03663-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Accepted: 10/10/2022] [Indexed: 11/16/2022] Open
Abstract
Background Advances in genetic and pharmaceutical technology and pediatric care have enabled treatment options for an increasing number of rare diseases in affected children. However, as current treatment options are primarily of palliative nature, the Health-Related Quality of Life (HRQoL) and mental health of this impaired population and their siblings are of increasing importance. Among children and adolescents with rare diseases, those who are technology-dependent carry a high disease burden and are selected as the target population in our study. In a cross-sectional observational design, the children’s HRQoL was assessed with the DISABKIDS (DCGM-37) as well as KIDSCREEN-27, while mental health was assessed with the Strengths and Difficulties Questionnaire (SDQ) by both the affected children, their parents, and siblings. Results Results of the study sample were compared to normative data. Affected children scored significantly lower than the norm on almost all HRQoL subscales as reported by parent and child. From the parental perspective, more mental health subscales were significantly impaired compared to the child’s perspective. Siblings showed no impairment in HRQoL as well as significantly fewer behavioral problems and higher prosocial behavior regarding their mental health compared to the norm. Conclusion Children and adolescents with rare diseases seem particularly impaired in social and emotional aspects of HRQoL and mental health. Interventions may focus primarily on promoting social skills, fostering prosocial behavior and peer relationships.
Collapse
Affiliation(s)
- Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany.
| | - Anna Liedtke
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany
| | - Lydia Morgenstern
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany
| | - Antonia Hoff
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany
| | - Anikó Csengoe-Norris
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany
| | - Jessika Johannsen
- Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jonas Denecke
- Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Claus Barkmann
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany
| | - Benjamin Grolle
- Department of Pediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Johannes Boettcher
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany.
| |
Collapse
|
18
|
Rillig A, Borof K, Breithardt G, Camm AJ, Crijns HJGM, Goette A, Kuck KH, Metzner A, Vardas P, Vettorazzi E, Wegscheider K, Zapf A, Kirchhof P. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation 2022; 146:836-847. [PMID: 35968706 DOI: 10.1161/circulationaha.122.060274] [Citation(s) in RCA: 35] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Accepted: 07/12/2022] [Indexed: 01/24/2023]
Abstract
BACKGROUND The randomized EAST-AFNET4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial-Atrial Fibrillation Network) demonstrated that early rhythm control (ERC) reduces adverse cardiovascular outcomes in patients with recently diagnosed atrial fibrillation and stroke risk factors. The effectiveness and safety of ERC in patients with multiple cardiovascular comorbidities is not known. METHODS These prespecified subanalyses of EAST-AFNET4 compared the effectiveness and safety of ERC with usual care (UC) stratified into patients with higher (CHA2DS2-VASc score ≥4) and lower comorbidity burden. Sensitivity analyses ignored sex (CHA2DS2-VA score). RESULTS EAST-AFNET4 randomized 1093 patients with CHA2DS2-VASc score ≥4 (74.8±6.8 years, 61% female) and 1696 with CHA2DS2-VASc score <4 (67.4±8.0 years, 37% female). ERC reduced the composite primary efficacy outcome of cardiovascular death, stroke, or hospitalization for worsening of heart failure or for acute coronary syndrome in patients with CHA2DS2-VASc score ≥4 (ERC, 127/549 patients with events; UC, 183/544 patients with events; hazard ratio [HR], 0.64 [0.51-0.81]; P < 0.001) but not in patients with CHA2DS2-VASc score <4 (ERC, 122/846 patients with events; UC, 133/850 patients with events; HR, 0.93 [0.73-1.19]; P=0.56, Pinteraction=0.037). The primary safety outcome (death, stroke, or serious adverse events of rhythm control therapy) was not different between study groups in patients with CHA2DS2-VASc score ≥4 (ERC, 112/549 patients with events; UC, 132/544 patients with events; HR, 0.84 [0.65, 1.08]; P=0.175), but occurred more often in patients with CHA2DS2-VASc scores <4 randomized to ERC (ERC, 119/846 patients with events; UC, 91/850 patients with events; HR, 1.39 [1.05-1.82]; P=0.019, Pinteraction=0.008). Life-threatening events or death were not different between groups (CHA2DS2-VASc score ≥4, ERC, 84/549 patients with event, UC, 96/544 patients with event; CHA2DS2-VASc scores <4, ERC, 75/846 patients with event, UC, 73/850 patients with event). When female sex was ignored for the creation of higher and lower risk groups (CHA2DS2-VA score), the Pinteraction was not significant for the primary efficacy outcome (P=0.25), but remained significant (P=0.044) for the primary safety outcome. CONCLUSIONS Patients with recently diagnosed atrial fibrillation and CHA2DS2-VASc score ≥4 should be considered for ERC to reduce cardiovascular outcomes, whereas those with fewer comorbidities may have less favorable outcomes with ERC. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique identifier: NCT01288352. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20. URL: https://www.isrctn.com/; Unique identifier: ISRCTN04708680.
Collapse
Affiliation(s)
- Andreas Rillig
- Department of Cardiology, University Heart and Vascular Center (A.R., K.B., A.M., P.K.), University Medical Center Hamburg-Eppendorf, Germany
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany (A.R., K.-H.K., A.M., K.W., P.K.)
| | - Katrin Borof
- Department of Cardiology, University Heart and Vascular Center (A.R., K.B., A.M., P.K.), University Medical Center Hamburg-Eppendorf, Germany
| | - Günter Breithardt
- Atrial Fibrillation Network (AFNET), Münster, Germany (G.B., A.G., K.-H.K., K.W., P.K.)
- Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany (G.B.)
| | - A John Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George's University of London, UK (A.J.C.)
| | - Harry J G M Crijns
- Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute, The Netherlands (H.J.G.M.C.)
| | - Andreas Goette
- Atrial Fibrillation Network (AFNET), Münster, Germany (G.B., A.G., K.-H.K., K.W., P.K.)
- St Vincenz Hospital, Paderborn, Germany (A.G.)
- Working Group of Molecular Electrophysiology, University Hospital Magdeburg, Germany (A.G.)
| | - Karl-Heinz Kuck
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany (A.R., K.-H.K., A.M., K.W., P.K.)
- Atrial Fibrillation Network (AFNET), Münster, Germany (G.B., A.G., K.-H.K., K.W., P.K.)
- LANS Cardio, Hamburg, Germany (K.-H.K.)
| | - Andreas Metzner
- Department of Cardiology, University Heart and Vascular Center (A.R., K.B., A.M., P.K.), University Medical Center Hamburg-Eppendorf, Germany
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany (A.R., K.-H.K., A.M., K.W., P.K.)
| | - Panos Vardas
- Heart Sector, Hygeia Hospitals Group, Athens, Greece (P.V.)
| | - Eik Vettorazzi
- Institute of Medical Biometry and Epidemiology (E.V., K.W., A.Z.), University Medical Center Hamburg-Eppendorf, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology (E.V., K.W., A.Z.), University Medical Center Hamburg-Eppendorf, Germany
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany (A.R., K.-H.K., A.M., K.W., P.K.)
- Atrial Fibrillation Network (AFNET), Münster, Germany (G.B., A.G., K.-H.K., K.W., P.K.)
| | - Antonia Zapf
- Institute of Medical Biometry and Epidemiology (E.V., K.W., A.Z.), University Medical Center Hamburg-Eppendorf, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center (A.R., K.B., A.M., P.K.), University Medical Center Hamburg-Eppendorf, Germany
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany (A.R., K.-H.K., A.M., K.W., P.K.)
- Atrial Fibrillation Network (AFNET), Münster, Germany (G.B., A.G., K.-H.K., K.W., P.K.)
- Institute of Cardiovascular Sciences, University of Birmingham, UK (P.K.)
| |
Collapse
|
19
|
Götze K, Bausewein C, Feddersen B, Fuchs A, Hot A, Hummers E, Icks A, Kirchner Ä, Kleinert E, Klosterhalfen S, Kolbe H, Laag S, Langner H, Lezius S, Meyer G, Montalbo J, Nauck F, Reisinger C, Rieder N, Schildmann J, Schunk M, Stanze H, Vogel C, Wegscheider K, Zapf A, Marckmann G, in der Schmitten J, Albert A, Alheid C, Bausewein C, Bruene M, Calles C, Camci H, Daubmann A, Dahlke S, Enger S, Feddersen B, Felder G, Fluck C, Freienstein A, Freytag T, Fuchs A, Icks A, in der Schmitten J, Hensel L, Hummers E, Hot A, Kirchner Ä, Kleinert E, Klosterhalfen S, Kolbe H, Laag S, Langner H, Lezius S, Marckmann G, Meyer G, Montalbo J, Nauck F, Nguyen T, Nowak A, Ossenberg M, Reisinger C, Reuter S, Rieder N, Riester T, Rosu I, Rösgen H, Salanta K, Sassi Z, Schildmann J, Schulenberg T, Schunk M, Sommer D, Stanze H, Stöhr A, Theuerkauf A, Thilo N, Tönjann J, Partowinia-Peters M, Prommersberger S, Przybylla S, Vogel C, Vomhof M, Wilken J, Zapf A, Zimprich J. Effectiveness of a complex regional advance care planning intervention to improve care consistency with care preferences: study protocol for a multi-center, cluster-randomized controlled trial focusing on nursing home residents (BEVOR trial). Trials 2022; 23:770. [PMID: 36096948 PMCID: PMC9465132 DOI: 10.1186/s13063-022-06576-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2022] [Accepted: 07/20/2022] [Indexed: 11/10/2022] Open
Abstract
Background According to recent legislation, facilitated advance care planning (ACP) for nursing home (NH) residents is covered by German sickness funds. However, the effects of ACP on patient-relevant outcomes have not been studied in Germany yet. This study investigates whether implementing a complex regional ACP intervention improves care consistency with care preferences in NH residents. Methods This is a parallel-group cluster-randomized controlled trial (cRCT) with 48 NHs (≈ 3840 resident beds) between 09/2019 and 02/2023. The intervention group will receive a complex, regional ACP intervention aiming at sustainable systems redesign at all levels (individual, institutional, regional). The intervention comprises comprehensive training of ACP facilitators, implementation of reliable ACP processes, organizational development in the NH and other relevant institutions of the regional healthcare system, and education of health professionals caring for the residents. Control group NHs will deliver care as usual. Primary outcome is the hospitalization rate during the 12-months observation period. Secondary outcomes include the rate of residents whose preferences were known and honored in potentially life-threatening events, hospital days, index treatments like resuscitation and artificial ventilation, advance directives, quality of life, psychological burden on bereaved families, and costs of care. The NHs will provide anonymous, aggregated data of all their residents on the primary outcome and several secondary outcomes (data collection 1). For residents who have given informed consent, we will evaluate care consistency with care preferences and further secondary outcomes, based on chart reviews and short interviews with residents, surrogates, and carers (data collection 2). Process evaluation will aim to explain barriers and facilitators, economic evaluation the cost implications. Discussion This study has the potential for high-quality evidence on the effects of a complex regional ACP intervention on NH residents, their families and surrogates, NH staff, and health care utilization in Germany. It is the first cRCT investigating a comprehensive regional ACP intervention that aims at improving patient-relevant clinical outcomes, addressing and educating multiple institutions and health care providers, besides qualification of ACP facilitators. Thereby, it can generate evidence on the potential of ACP to effectively promote patient-centered care in the vulnerable population of frail and often chronically ill elderly. Trial registration ClinicalTrials.gov ID NCT04333303. Registered 30 March 2020. Supplementary Information The online version contains supplementary material available at 10.1186/s13063-022-06576-3.
Collapse
|
20
|
Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns HJGM, Goette A, Wegscheider K, Zapf A, Camm AJ, Metzner A, Kirchhof P. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST - AFNET 4 trial. Eur Heart J 2022; 43:4127-4144. [PMID: 36036648 PMCID: PMC9584752 DOI: 10.1093/eurheartj/ehac471] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 08/10/2022] [Accepted: 08/12/2022] [Indexed: 11/22/2022] Open
Abstract
Aims A strategy of systematic, early rhythm control (ERC) improves cardiovascular outcomes in patients with atrial fibrillation (AF). It is not known how this outcome-reducing effect is mediated. Methods and results Using the Early treatment of Atrial Fibrillation for Stroke prevention Trial (EAST—AFNET 4) data set, potential mediators of the effect of ERC were identified in the total study population at 12-month follow up and further interrogated by use of a four-way decomposition of the treatment effect in an exponential model predicting future primary outcome events. Fourteen potential mediators of ERC were identified at the 12-month visit. Of these, sinus rhythm at 12 months explained 81% of the treatment effect of ERC compared with usual care during the remainder of follow up (4.1 years). In patients not in sinus rhythm at 12 months, ERC did not reduce future cardiovascular outcomes (hazard ratio 0.94, 95% confidence interval 0.65–1.67). Inclusion of AF recurrence in the model only explained 31% of the treatment effect, and inclusion of systolic blood pressure at 12 months only 10%. There was no difference in outcomes in patients who underwent AF ablation compared with those who did not undergo AF ablation. Conclusion The effectiveness of early rhythm control is mediated by the presence of sinus rhythm at 12 months in the EAST-AFNET 4 trial. Clinicians implementing ERC should aim for rapid and sustained restoration of sinus rhythm in patients with recently diagnosed AF and cardiovascular comorbidities.
Collapse
Affiliation(s)
- L Eckardt
- Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany.,2Atrial Fibrillation Network (AFNET), Münster, Germany
| | - S Sehner
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany
| | - A Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany
| | - K Borof
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Germany
| | - G Breithardt
- Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany.,2Atrial Fibrillation Network (AFNET), Münster, Germany
| | - H J G M Crijns
- Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Netherlands
| | - A Goette
- 2Atrial Fibrillation Network (AFNET), Münster, Germany.,Department of Cardiology, Vincenz-Krankenhaus Paderborn, Germany
| | - K Wegscheider
- 2Atrial Fibrillation Network (AFNET), Münster, Germany.,Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany.,DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Berlin, Germany
| | - A Zapf
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany.,DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Berlin, Germany
| | - A J Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, UK
| | - A Metzner
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Germany.,DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Berlin, Germany
| | - P Kirchhof
- 2Atrial Fibrillation Network (AFNET), Münster, Germany.,Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Germany.,DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Berlin, Germany.,Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
21
|
Schnabel RB, Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, Camm AJ, Casadei B, Chua W, Dagres N, de Melis M, Desteghe L, Diederichsen SZ, Duncker D, Eckardt L, Eisert C, Engler D, Fabritz L, Freedman B, Gillet L, Goette A, Guasch E, Svendsen JH, Hatem SN, Haeusler KG, Healey JS, Heidbuchel H, Hindricks G, Hobbs FDR, Hübner T, Kotecha D, Krekler M, Leclercq C, Lewalter T, Lin H, Linz D, Lip GYH, Løchen ML, Lucassen W, Malaczynska-Rajpold K, Massberg S, Merino JL, Meyer R, Mont L, Myers MC, Neubeck L, Niiranen T, Oeff M, Oldgren J, Potpara TS, Psaroudakis G, Pürerfellner H, Ravens U, Rienstra M, Rivard L, Scherr D, Schotten U, Shah D, Sinner MF, Smolnik R, Steinbeck G, Steven D, Svennberg E, Thomas D, True Hills M, van Gelder IC, Vardar B, Palà E, Wakili R, Wegscheider K, Wieloch M, Willems S, Witt H, Ziegler A, Daniel Zink M, Kirchhof P. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace 2022; 25:6-27. [PMID: 35894842 PMCID: PMC9907557 DOI: 10.1093/europace/euac062] [Citation(s) in RCA: 50] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 04/11/2022] [Indexed: 11/13/2022] Open
Abstract
Despite marked progress in the management of atrial fibrillation (AF), detecting AF remains difficult and AF-related complications cause unacceptable morbidity and mortality even on optimal current therapy. This document summarizes the key outcomes of the 8th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eighty-three international experts met in Hamburg for 2 days in October 2021. Results of the interdisciplinary, hybrid discussions in breakout groups and the plenary based on recently published and unpublished observations are summarized in this consensus paper to support improved care for patients with AF by guiding prevention, individualized management, and research strategies. The main outcomes are (i) new evidence supports a simple, scalable, and pragmatic population-based AF screening pathway; (ii) rhythm management is evolving from therapy aimed at improving symptoms to an integrated domain in the prevention of AF-related outcomes, especially in patients with recently diagnosed AF; (iii) improved characterization of atrial cardiomyopathy may help to identify patients in need for therapy; (iv) standardized assessment of cognitive function in patients with AF could lead to improvement in patient outcomes; and (v) artificial intelligence (AI) can support all of the above aims, but requires advanced interdisciplinary knowledge and collaboration as well as a better medico-legal framework. Implementation of new evidence-based approaches to AF screening and rhythm management can improve outcomes in patients with AF. Additional benefits are possible with further efforts to identify and target atrial cardiomyopathy and cognitive impairment, which can be facilitated by AI.
Collapse
Affiliation(s)
- Renate B Schnabel
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,German Centre for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lübeck, Hamburg, Germany
| | | | - Elena Arbelo
- Arrhythmia Section, Cardiology Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain,IDIBAPS, Institut d'Investigació August Pi i Sunyer, Barcelona, Spain,CIBERCV, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Polyclinic of Modena, Modena, Italy
| | - Serge Boveda
- Cardiology—Heart Rhythm Management Department, Clinique Pasteur, 45 Avenue de Lombez, 31076 Toulouse, France,Universiteit Ziekenhuis, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | | | - A John Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, St. George's University of London, London, UK
| | - Barbara Casadei
- RDM, Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
| | - Winnie Chua
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Nikolaos Dagres
- Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany
| | - Mirko de Melis
- Medtronic Bakken Research Center, Maastricht, The Netherlands
| | - Lien Desteghe
- Research Group Cardiovascular Diseases, University of Antwerp, Antwerp, Belgium,Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium,Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium,Heart Centre Hasselt, Jessa Hospital, Hasselt, Belgium
| | - Søren Zöga Diederichsen
- Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
| | - David Duncker
- Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
| | - Lars Eckardt
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Division of Electrophysiology, Department of Cardiology and Angiology, Münster, Germany
| | | | - Daniel Engler
- Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,German Centre for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lübeck, Hamburg, Germany
| | - Larissa Fabritz
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,German Centre for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lübeck, Hamburg, Germany,Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK,University Center of Cardiovascular Science Hamburg, Hamburg, Germany
| | - Ben Freedman
- Heart Research Institute, The University of Sydney, Sydney, Australia
| | | | - Andreas Goette
- Atrial Fibrillation Network (AFNET), Muenster, Germany,St Vincenz Hospital, Paderborn, Germany
| | - Eduard Guasch
- Arrhythmia Section, Cardiology Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain,IDIBAPS, Institut d'Investigació August Pi i Sunyer, Barcelona, Spain,CIBERCV, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain
| | - Jesper Hastrup Svendsen
- Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark,Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | - Karl Georg Haeusler
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany
| | - Jeff S Healey
- Population Health Research Institute, McMaster University Hamilton, ON, Canada
| | - Hein Heidbuchel
- Research Group Cardiovascular Diseases, University of Antwerp, Antwerp, Belgium,Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
| | - Gerhard Hindricks
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany
| | | | | | - Dipak Kotecha
- University of Birmingham & University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
| | | | | | - Thorsten Lewalter
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Hospital Munich South, Department of Cardiology, Munich, Germany,Department of Cardiology, University of Bonn, Bonn, Germany
| | - Honghuang Lin
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
| | - Dominik Linz
- Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands,Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Maja Lisa Løchen
- Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
| | - Wim Lucassen
- Amsterdam UMC (location AMC), Department General Practice, Amsterdam, The Netherlands
| | | | - Steffen Massberg
- Department of Cardiology, University Hospital, LMU Munich, Munich, Germany,German Centre for Cardiovascular Research (DZHK), partner site: Munich Heart Alliance, Munich, Germany
| | - Jose L Merino
- Arrhythmia & Robotic EP Unit, La Paz University Hospital, IDIPAZ, Madrid, Spain
| | | | - Lluıs Mont
- Arrhythmia Section, Cardiology Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain,IDIBAPS, Institut d'Investigació August Pi i Sunyer, Barcelona, Spain,CIBERCV, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain
| | | | - Lis Neubeck
- Arrhythmia & Robotic EP Unit, La Paz University Hospital, IDIPAZ, Madrid, Spain
| | - Teemu Niiranen
- Medtronic, Dublin, Ireland,Centre for Cardiovascular Health Edinburgh Napier University, Edinburgh, UK
| | - Michael Oeff
- Atrial Fibrillation Network (AFNET), Muenster, Germany
| | - Jonas Oldgren
- University of Turku and Turku University Hospital, Turku, Finland
| | | | - George Psaroudakis
- Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Helmut Pürerfellner
- School of Medicine, Belgrade University, Cardiology Clinic, University Clinical Centre of Serbia, Belgrade, Serbia
| | - Ursula Ravens
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Bayer AG, Leverkusen, Germany
| | - Michiel Rienstra
- Ordensklinikum Linz, Elisabethinen, Cardiological Department, Linz, Austria
| | - Lena Rivard
- Institute of Experimental Cardiovascular Medicine, University Hospital Freiburg, Freiburg, Germany
| | - Daniel Scherr
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Ulrich Schotten
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Montreal Heart Institute, University of Montreal, Montreal, Canada
| | - Dipen Shah
- Division of Cardiology, Medical University of Graz, Graz, Austria
| | - Moritz F Sinner
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Amsterdam UMC (location AMC), Department General Practice, Amsterdam, The Netherlands,Royal Brompton Hospital, London, UK
| | | | - Gerhard Steinbeck
- Atrial Fibrillation Network (AFNET), Muenster, Germany,MUMC+, Maastricht, The Netherlands
| | - Daniel Steven
- Atrial Fibrillation Network (AFNET), Muenster, Germany,University Hospital of Geneva, Cardiac Electrophysiology Unit, Geneva, Switzerland
| | - Emma Svennberg
- Center for Cardiology at Clinic Starnberg, Starnberg, Germany
| | - Dierk Thomas
- Atrial Fibrillation Network (AFNET), Muenster, Germany,University Hospital Cologne, Heart Center, Department of Electrophysiology, Cologne, Germany,Karolinska Institutet, Department of Medicine Huddinge, Karolinska University Hospital, Stockholm, Sweden,Department of Cardiology, Medical University Hospital, Heidelberg, Germany
| | - Mellanie True Hills
- HCR (Heidelberg Center for Heart Rhythm Disorders), Medical University Hospital Heidelberg, Heidelberg, Germany
| | - Isabelle C van Gelder
- DZHK (German Center for Cardiovascular Research), partner site Heidelberg/Mannheim, Heidelberg, Germany
| | - Burcu Vardar
- Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Elena Palà
- StopAfib.org, American Foundation for Women’s Health, Decatur, TX, USA
| | - Reza Wakili
- Atrial Fibrillation Network (AFNET), Muenster, Germany,Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
| | - Karl Wegscheider
- Atrial Fibrillation Network (AFNET), Muenster, Germany,German Centre for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lübeck, Hamburg, Germany,Neurovascular Research Laboratory, Vall d’Hebron Institute of Research (VHIR), Autonomous University of Barcelona, Barcelona, Spain
| | - Mattias Wieloch
- Department of Cardiology and Vascular Medicine, Westgerman Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany,Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany
| | - Stephan Willems
- Atrial Fibrillation Network (AFNET), Muenster, Germany,German Centre for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lübeck, Hamburg, Germany,Department of Coagulation Disorders, Skane University Hospital, Lund University, Malmö, Sweden
| | | | | | - Matthias Daniel Zink
- Asklepios Hospital St Georg, Department of Cardiology and Internal Intensive Care Medicine, Faculty of Medicine, Semmelweis University Campus Hamburg, Hamburg, Germany
| | - Paulus Kirchhof
- Corresponding author. Tel: +49 40 7410 52438; Fax: +49 40 7410 55862. E-mail address:
| |
Collapse
|
22
|
Goette A, Borof K, Breithardt G, Camm AJ, Crijns HJGM, Kuck KH, Wegscheider K, Kirchhof P. Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. J Am Coll Cardiol 2022; 80:283-295. [PMID: 35863844 DOI: 10.1016/j.jacc.2022.04.058] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 04/14/2022] [Accepted: 04/18/2022] [Indexed: 11/19/2022]
Abstract
BACKGROUND Whether atrial fibrillation (AF) pattern or timing of AF therapy modifies the effectiveness of early rhythm control (ERC) is not known. OBJECTIVES This study sought to compare clinical characteristics and outcomes in patients presenting with different AF patterns on ERC vs usual care. METHODS The effects of ERC were compared in first-diagnosed AF (FDAF), paroxysmal AF (paroxAF), and persistent AF (persAF) in this prespecified analysis of the EAST-AFNET 4 (Early treatment of atrial fibrillation for stroke prevention) trial. Associations between AF pattern and primary outcomes (first primary outcome: cardiovascular death, stroke, and hospitalization for heart failure and acute coronary syndrome; second primary outcome: nights spent in hospital per year) were compared over a mean follow-up of 5.1 years. Changes in health-related quality of life were assessed by the EQ-5D. RESULTS FDAF patients (n = 1,048, enrolled 7 days after diagnosing AF) were slightly older (71 years of age, 48.0% female) than patients with paroxAF (n = 994, 70 years of age, 50.0% female) and persAF (n = 743, 70 years of age, 38.0% female). ERC reduced the primary outcome in all 3 AF patterns. Hospitalizations for acute coronary syndrome were highest in FDAF (incidence rate ratio [IRR]: 1.50; 95% CI: 0.83-2.69; P for interaction = 0.032) compared with paroxAF (IRR: 0.64; 95% CI: 0.32-1.25) and persAF (IRR: 0.50; 95% CI: 0.25-1.00). FDAF patients spent more nights in hospital (IRR: 1.38; 95% CI: 1.12-1.70; P for interaction = 0.004) than paroxAF (IRR: 0.84; 95% CI: 0.67-1.03), and persAF (IRR: 1.02; 95% CI: 0.80-1.30) patients. ERC improved health-related quality of life (EQ-5D score) in patients with paroxAF and persAF but not in patients with FDAF (P = 0.019). CONCLUSIONS ERC reduces the first primary composite outcome in all AF patterns. Patients with FDAF are at high risk for hospitalization and acute coronary syndrome, particularly on ERC. (Early treatment of atrial fibrillation for stroke prevention trial; ISRCTN04708680; Early Treatment of Atrial Fibrillation for Stroke Prevention Trial [EAST]; NCT01288352; Early treatment of Atrial fibrillation for Stroke prevention Trial [EAST]; EudraCT2010-021258-20).
Collapse
Affiliation(s)
- Andreas Goette
- Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, Paderborn, Germany; AFNET e.V., Münster, Germany.
| | - Katrin Borof
- AFNET e.V., Münster, Germany; Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Günter Breithardt
- AFNET e.V., Münster, Germany; Department of Cardiology and Angiology, University Hospital Münster, Münster, Germany
| | - A John Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, London, United Kingdom
| | - Harry J G M Crijns
- Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands
| | | | - Karl Wegscheider
- Institute for Medical Biometry and Epidemiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
| |
Collapse
|
23
|
Nabauer M, Gerth A, Wegscheider K, Buchholz A, Haeusler KG, Ravens U, Sprenger C, Tebbe U, Kirchhof P, Breithardt G, Steinbeck G. Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET): Authors' reply. Europace 2022; 24:1872-1873. [PMID: 35655121 DOI: 10.1093/europace/euac084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Michael Nabauer
- Medical Clinic I, Ludwig-Maximilians-University, Munich, Germany
| | - Andrea Gerth
- Medical Clinic I, Ludwig-Maximilians-University, Munich, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anika Buchholz
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Ursula Ravens
- Institute for Experimental Cardiovascular Medicine, University Heart Center, University of Freiburg, Freiburg, Germany; and Institute of Physiology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden
| | - Claudia Sprenger
- Department of Medicine I, Brandenburg Municipal Hospital, Brandenburg, Germany
| | - Ulrich Tebbe
- Department of Cardiology, Hospital Detmold, Detmold, Germany
| | - Paulus Kirchhof
- Department of Cardiology/Angiology, University Hospital Eppendorf, Hamburg, Germany
| | - Günter Breithardt
- Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
| | | |
Collapse
|
24
|
Andreas S, Schulz H, Volkert J, Lüdemann J, Dehoust M, Sehner S, Suling A, Wegscheider K, Ausín B, Canuto A, Crawford MJ, Da Ronch C, Grassi L, Hershkovitz Y, Muñoz M, Quirk A, Rotenstein O, Belén Santos-Olmo A, Shalev A, Weber K, Wittchen HU, Härter M. Incidence and risk factors of mental disorders in the elderly: The European MentDis_ICF65+ study. Aust N Z J Psychiatry 2022; 56:551-559. [PMID: 34250828 DOI: 10.1177/00048674211025711] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
OBJECTIVE While incidence rates of depression and anxiety disorders in the elderly have been comprehensively investigated, the incidence rates of other mental disorders have rarely been researched. The incidence rate and predictors of various mental disorders in the elderly were evaluated in different European and associated countries. METHODS A cross-sectional and longitudinal multi-centre survey of Diagnostic and Statistical Manual of Mental Disorders (4th ed.) diagnoses was conducted in different European and associated countries (Germany, Italy, Spain, Switzerland, the United Kingdom and Israel) to collect data on the prevalence and incidence of mental disorders in the elderly. The sample size of the longitudinal wave was N = 2592 elderly. RESULTS The overall 1-year incidence rate for any mental disorder in the elderly is 8.65%. At 5.18%, any anxiety disorder had the highest incidence rate across all diagnostic groups. The incidence rate for any affective disorder was 2.97%. The lowest incidence rates were found for agoraphobia (1.37%) and panic disorder (1.30%). Risk factors for the development of any mental disorder were never having been married, no religious affiliation, a higher number of physical illnesses and a lower quality of life. CONCLUSION In comparison to other studies, lower incidence rates for any affective disorder and middle-range incidence for any anxiety disorder were found. To the authors' knowledge, no prior studies have reported 1-year incidence rates for somatoform disorder, bipolar disorder and substance misuse in community-dwelling elderly. These findings indicate the need to raise awareness of psychosocial problems in the elderly and to ensure adequate availability of mental health services.
Collapse
Affiliation(s)
- Sylke Andreas
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Department of Clinical Psychology, Psychotherapy and Psychoanalysis, Institute for Psychology, Alpen-Adria-Universität Klagenfurt, Klagenfurt am Wörthersee, Austria.,Department of Psychology, Witten/Herdecke University, Witten, Germany
| | - Holger Schulz
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jana Volkert
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Department of Psychosocial Prevention, Heidelberg University, Heidelberg, Germany
| | - Jonas Lüdemann
- Department of Clinical Psychology, Psychotherapy and Psychoanalysis, Institute for Psychology, Alpen-Adria-Universität Klagenfurt, Klagenfurt am Wörthersee, Austria
| | - Maria Dehoust
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Susanne Sehner
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Berta Ausín
- School of Psychology, Complutense University of Madrid, Madrid, Spain
| | | | - Michael J Crawford
- College Centre for Quality Improvement, Royal College of Psychiatrists, London, UK
| | - Chiara Da Ronch
- Institute of Psychiatry, Department of Biomedical and Specialty Surgical Sciences, Universita degli Studi di Ferrara, Ferrara, Italy
| | - Luigi Grassi
- Institute of Psychiatry, Department of Biomedical and Specialty Surgical Sciences, Universita degli Studi di Ferrara, Ferrara, Italy
| | - Yael Hershkovitz
- Department of Psychiatry, Hadassah University Medical Center, Jerusalem, Israel
| | - Manuel Muñoz
- School of Psychology, Complutense University of Madrid, Madrid, Spain
| | - Alan Quirk
- College Centre for Quality Improvement, Royal College of Psychiatrists, London, UK
| | - Ora Rotenstein
- Department of Psychiatry, Hadassah University Medical Center, Jerusalem, Israel
| | | | - Arieh Shalev
- Department of Psychiatry, Hadassah University Medical Center, Jerusalem, Israel.,Department of Psychiatry, NY Langone Medical Center, New York, NY, USA
| | - Kerstin Weber
- Department of Psychiatry, University of Geneva, Geneva, Switzerland
| | - Hans-Ulrich Wittchen
- Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.,Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität München, München, Germany
| | - Martin Härter
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
25
|
Gerloff C, Heise KF, Schulz R, Hummel FC, Wolf S, Zapf A, Cordes D, Gerloff C, Heise KF, Hummel F, Schulz R, Wolf S, Haevernick K, Krüger H, Krause L, Suling A, Wegscheider K, Zapf A, Dressnandt J, Schäpers B, Schrödl C, Hauptmann B, Kirchner A, Brault A, Gutschalk A, Richter C, Nowak DA, Veldema J, Koch G, Maiella M, Dohle C, Jettkowski K, Pilz M, Hamzei F, Olischer L, Renner C, Groß M, Jöbges M, Voller B. A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of transcranial direct current stimulation to the motor cortex after stroke (NETS): study protocol. Neurol Res Pract 2022; 4:14. [PMID: 35430801 PMCID: PMC9014609 DOI: 10.1186/s42466-022-00171-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 01/20/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Introduction
The WHO estimates that each year 5 million people are left permanently disabled after stroke. Adjuvant treatments to promote the effects of rehabilitation are urgently needed. Cortical excitability and neuroplasticity can be enhanced by non-invasive brain stimulation but evidence from sufficiently powered, randomized controlled multi-center clinical trials is absent.
Methods
Neuroregeneration enhanced by transcranial direct current stimulation (tDCS) in stroke (NETS) tested efficacy and safety of anodal tDCS to the primary motor cortex of the lesioned hemisphere in the subacute phase (day 5–45) after cerebral ischemia. Stimulation was combined with standardized rehabilitative training and repeatedly applied in 10 sessions over a period of 2 weeks in a planned sample of 120 patients. Primary outcome parameter was upper-extremity function at the end of the 2-weeks intervention period of active treatment or placebo (1:1 randomization), measured by the upper-extremity Fugl-Meyer assessment. Sustainability of the treatment effect was evaluated by additional follow-up visits after 30 and 90 days. Further secondary endpoints included metrics of arm and hand function, stroke impact scale, and the depression module of the patient health questionnaire.
Perspective
NETS was aimed at providing evidence for an effective and safe adjuvant treatment for patients after stroke.
Trial registration: ClinicalTrials.gov Identifier NCT00909714. Registered May 28, 2009.
Collapse
|
26
|
Mallon T, Schäfer I, Fuchs A, Gensichen J, Maier W, Riedel-Heller S, König HH, Mergenthal K, Schön G, Wegscheider K, Weyerer S, Wiese B, van den Bussche H, Scherer M. The moderating effects of social support and depressive symptoms on pain among elderly multimorbid patients-data from the multicentre, prospective, observational cohort study MultiCare. Aging Ment Health 2022; 26:803-809. [PMID: 33949271 DOI: 10.1080/13607863.2021.1916882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVES Depressive symptoms and chronic pain are common among patients with multimorbidity creating a complex medical condition for both the patient and the general practitioner. Perceived social support may function as a protective measure. UNLABELLED To examine the impact of perceived social support as a potential moderator between depressive symptoms and pain intensity and pain disability in daily activities in multimorbid patients aged 75+. METHOD Data from 3,189 patients of the German longitudinal cohort study MultiCare were obtained at baseline and follow-ups during 5 years. Multilevel linear mixed-effects analyses were conducted for pain intensity (model 1) and pain disability in daily activities (model 2). The interaction term social support by depression score was included to test for moderation. RESULTS The interaction between social support and depressive symptoms was significantly associated with the pain intensity score 0.41 (SE=.17; 95-CI[.08;.74]) but not with the pain disability score 0.35 (SE=.19; 95-CI[-.01;.72]). Additionally, men and individuals with medium or higher educational level showed reduced pain intensity and disability scores. Pain disability scores increased with age and depressive symptoms. Increased pain scores were also found for body mass index and burden of multimorbidity. CONCLUSION Perceived social support amplified the association of depressive symptoms on pain intensity and did not show a protective function. The high scores of perceived social support among the participants may point to the practice of secondary gain due to the patients immense health burden.
Collapse
Affiliation(s)
- Tina Mallon
- Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Ingmar Schäfer
- Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Angela Fuchs
- Institute of General Practice, University Düsseldorf, Düsseldorf, Germany
| | - Jochen Gensichen
- Institute of General Practice and Family Medicine, University Hospital of Ludwig-Maximilians-University Munich, Munich, Germany
| | - Wolfgang Maier
- Department of Psychiatry and Psychotherapy, University Bonn, Bonn, Germany
| | - Steffi Riedel-Heller
- Institute for Social Medicine, Occupational Health and Public Health, University Leipzig, Leipzig, Germany
| | - Hans-Helmut König
- Department of Health Economics and Health Services Research, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Karola Mergenthal
- Institute of General Practice, Goethe University Frankfurt Am Main, Frankfurt Am Main, Germany
| | - Gerhard Schön
- Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Siegfried Weyerer
- Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Birgitt Wiese
- Institute of General Practice, WG Medical Statistics and IT-Infrastructure, Hannover Medical School, Hannover, Germany
| | - Hendrik van den Bussche
- Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Martin Scherer
- Department of Primary Medical Care, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
27
|
Wicke FS, Dinh TS, Riedel-Heller S, Weyerer S, König HH, Gensichen J, Schön G, Wegscheider K, Bickel H, Fuchs A, Schäfer I, van den Bussche H, Scherer M, Mergenthal K. Predictors of change in depressive symptoms in older and multimorbid patients: a longitudinal analysis of the multicare cohort. Aging Ment Health 2022; 26:818-827. [PMID: 33764211 DOI: 10.1080/13607863.2021.1902470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Depression in older adults is becoming an increasing concern. As depressive symptoms change over time, it is important to understand the determinants of change in depressive symptoms. The aim of our study is to use a longitudinal study design to explore the predictors of change, remission and incident depression in older patients with multimorbidity. METHODS Data from the MultiCare cohort study were used. The cohort studied 3,189 multimorbid general practice patients aged 65-85. Data were collected during personal interviews. Depressive symptoms were assessed using the Geriatric Depression Scale (GDS-15). Predictors of change in depressive symptoms were determined using multivariate linear regression, while multivariate logistic regression was used to analyze predictors of remission and incident depression. Models included depressive symptoms at baseline and follow-up, socio-demographics and data on health status and social support. RESULTS Overall, 2,746 participants with complete follow-up data were analyzed. Mean age was 74.2 years, 59.2% were female, and 11.3% were classified as depressed at baseline. Burden of multimorbidity and social support were statistically significant predictors in all regression analyses. Further predictors of change in depressive symptoms were: income, pain, nursing grade, self-rated health and self-efficacy. LIMITATIONS The sample size for prediction of remission limited statistical certainty. Assessment of depressive symptoms using GDS-15 differs from routine clinical diagnoses of depression. CONCLUSIONS Predictors of change in depressive symptoms in older multimorbid patients are similar to those predicting remission and incident depression, and do not seem to differ significantly from other older patient populations with depressive symptoms.
Collapse
Affiliation(s)
- Felix Sebastian Wicke
- Institute of General Practice, Goethe-University Frankfurt, Frankfurt am Main, Germany
| | - Truc Sophia Dinh
- Institute of General Practice, Goethe-University Frankfurt, Frankfurt am Main, Germany
| | - Steffi Riedel-Heller
- Institute for Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany
| | - Siegfried Weyerer
- Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Hans-Helmut König
- Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Jochen Gensichen
- Institute of General Practice/Family Medicine, University Hospital of LMU Munich, Munich, Germany
| | - Gerhard Schön
- Department of Medical Biometry and Epidemiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Horst Bickel
- Department of Psychiatry, Technical University of Munich, Munich, Germany
| | - Angela Fuchs
- Institute of General Practice, Medical Faculty of the Heinrich Heine University Duesseldorf, Duesseldorf, Germany
| | - Ingmar Schäfer
- Department of Primary Medical Care, Center of Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Hendrik van den Bussche
- Department of Primary Medical Care, Center of Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Martin Scherer
- Department of Primary Medical Care, Center of Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karola Mergenthal
- Institute of General Practice, Goethe-University Frankfurt, Frankfurt am Main, Germany
| | | |
Collapse
|
28
|
Völler H, Bindl D, Nagels K, Hofmann R, Vettorazzi E, Wegscheider K, Fleck E, Störk S, Nagel E. The First Year of Noninvasive Remote Telemonitoring in Chronic Heart Failure Is not Cost Saving but Improves Quality of Life: The Randomized Controlled CardioBBEAT Trial. Telemed J E Health 2022; 28:1613-1622. [PMID: 35325562 PMCID: PMC9700331 DOI: 10.1089/tmj.2022.0021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 01/17/2022] [Accepted: 01/19/2022] [Indexed: 11/13/2022] Open
Abstract
Introduction: Remote telemonitoring (RTM) for patients with chronic heart failure (HF) holds promise to improve prognosis and well-being beyond the standard of care (SoC). The CardioBBEAT trial assessed the health economic and clinical impact of an interactive bidirectional RTM system (Motiva®) versus SoC for patients with HF and a reduced ejection fraction (HFrEF), in Germany. Methods: This multicenter, randomized controlled trial enrolled 621 patients with HFrEF (mean age 63.0 ± 11.5 years, 88% men). The primary endpoint was the integrated effect of the intervention on total costs and nonhospitalized days alive after 12 months, reported as incremental cost-effectiveness ratio (ICER). Costs (in k€) were based on actual charges of patients' statutory health insurance. Among secondary outcome measures were mortality and disease-specific quality of life. Results: We found a neutral effect on nonhospitalized days alive (RTM mean 341 ± 59 days, SoC 346 ± 45 days; p = 0.298) associated with increased total costs (RTM 18.5 ± 39.5 k€, SoC 12.8 ± 22.0 k€; p = 0.046). This yielded an ICER of -1.15 k€/day. RTM did not impact mortality risk. All quality of life scales were consistently and meaningfully improved in the RTM group at 12 months compared to SoC (all p < 0.01). Conclusions: The first 12 months of RTM were not cost-effective compared to SoC in patients with HFrEF, but associated with a relevant improvement in disease-specific quality of life. The balanced assessment of the potential benefit of RTM requires integration of both the societal and patient perspective. ClinTrials.gov (NCT02293252).
Collapse
Affiliation(s)
- Heinz Völler
- Center of Rehabilitation Research, University of Potsdam, Potsdam, Germany
- Klinik am See, Rüdersdorf, Germany
| | - Dominik Bindl
- Chair of Healthcare Management and Health Services Research, University of Bayreuth, Bayreuth, Germany
| | - Klaus Nagels
- Chair of Healthcare Management and Health Services Research, University of Bayreuth, Bayreuth, Germany
| | - Reiner Hofmann
- Chair of Healthcare Management and Health Services Research, University of Bayreuth, Bayreuth, Germany
| | - Eik Vettorazzi
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
| | - Eckart Fleck
- German Heart Institute Berlin, University of Berlin, Berlin, Germany
| | - Stefan Störk
- Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany
- Department of Internal Medicine I, University Hospital Würzburg, Germany, Würzburg, Germany
| | - Eckhard Nagel
- Institute for Healthcare Management and Health Science, University of Bayreuth, Bayreuth, Germany
| |
Collapse
|
29
|
Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Gessler N, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Ng GA, Schnabel RB, Suling A, Szumowski L, Themistoclakis S, Vardas P, van Gelder IC, Wegscheider K, Kirchhof P. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022; 43:1219-1230. [PMID: 34447995 PMCID: PMC8934687 DOI: 10.1093/eurheartj/ehab593] [Citation(s) in RCA: 73] [Impact Index Per Article: 36.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 08/06/2021] [Accepted: 08/17/2021] [Indexed: 01/22/2023] Open
Abstract
AIMS Clinical practice guidelines restrict rhythm control therapy to patients with symptomatic atrial fibrillation (AF). The EAST-AFNET 4 trial demonstrated that early, systematic rhythm control improves clinical outcomes compared to symptom-directed rhythm control. METHODS AND RESULTS This prespecified EAST-AFNET 4 analysis compared the effect of early rhythm control therapy in asymptomatic patients (EHRA score I) to symptomatic patients. Primary outcome was a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome, analyzed in a time-to-event analysis. At baseline, 801/2633 (30.4%) patients were asymptomatic [mean age 71.3 years, 37.5% women, mean CHA2DS2-VASc score 3.4, 169/801 (21.1%) heart failure]. Asymptomatic patients randomized to early rhythm control (395/801) received similar rhythm control therapies compared to symptomatic patients [e.g. AF ablation at 24 months: 75/395 (19.0%) in asymptomatic; 176/910 (19.3%) symptomatic patients, P = 0.672]. Anticoagulation and treatment of concomitant cardiovascular conditions was not different between symptomatic and asymptomatic patients. The primary outcome occurred in 79/395 asymptomatic patients randomized to early rhythm control and in 97/406 patients randomized to usual care (hazard ratio 0.76, 95% confidence interval [0.6; 1.03]), almost identical to symptomatic patients. At 24 months follow-up, change in symptom status was not different between randomized groups (P = 0.19). CONCLUSION The clinical benefit of early, systematic rhythm control was not different between asymptomatic and symptomatic patients in EAST-AFNET 4. These results call for a shared decision discussing the benefits of rhythm control therapy in all patients with recently diagnosed AF and concomitant cardiovascular conditions (EAST-AFNET 4; ISRCTN04708680; NCT01288352; EudraCT2010-021258-20).
Collapse
Affiliation(s)
- Stephan Willems
- Asklepios Hospital St. Georg, Department of Cardiology and Internal intensive care medicine, Faculty of Medicine, Semmelweis University Campus Hamburg, Hamburg, Germany
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Luebeck, Berlin, Germany
- Atrial Fibrillation Network (AFNET), Münster, Germany
| | - Katrin Borof
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg, Martinistraße 52, Hamburg 20246, Germany
| | - Axel Brandes
- Department of Cardiology, Odense University Hospital, Denmark
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - Günter Breithardt
- Atrial Fibrillation Network (AFNET), Münster, Germany
- Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany
| | - A John Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George’s University of London, UK
| | - Harry J G M Crijns
- Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Netherlands
| | - Lars Eckardt
- Atrial Fibrillation Network (AFNET), Münster, Germany
- Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany
| | - Nele Gessler
- Asklepios Hospital St. Georg, Department of Cardiology and Internal intensive care medicine, Faculty of Medicine, Semmelweis University Campus Hamburg, Hamburg, Germany
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Luebeck, Berlin, Germany
| | - Andreas Goette
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- St. Vincenz Hospital, Paderborn, Germany
- Working Group of Molecular Electrophysiology, University Hospital Magdeburg, Germany
| | - Laurent M Haegeli
- University Hospital Zurich, Zurich, Switzerland
- Division of Cardiology, Medical University Department, Kantonsspital Aarau, Switzerland
| | - Hein Heidbuchel
- University Hospital Antwerp and Antwerp University, Antwerp, Belgium
| | - Josef Kautzner
- Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - G André Ng
- Department of Cardiovascular Sciences, University of Leicester, National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
| | - Renate B Schnabel
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Luebeck, Berlin, Germany
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg, Martinistraße 52, Hamburg 20246, Germany
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg, Eppendorf, Germany
| | - Lukasz Szumowski
- Arrhythmia Center of the National Institute of Cardiology, Medical Division of Cardinal Stefan Wyszynski University in Warsaw, Warsaw, Poland
| | | | - Panos Vardas
- Heart Sector, Hygeia Hospitals Group, Athens, Greece
| | - Isabelle C van Gelder
- University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Karl Wegscheider
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Luebeck, Berlin, Germany
- Atrial Fibrillation Network (AFNET), Münster, Germany
- Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Paulus Kirchhof
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Luebeck, Berlin, Germany
- Atrial Fibrillation Network (AFNET), Münster, Germany
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg, Martinistraße 52, Hamburg 20246, Germany
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
30
|
Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Elvan A, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Kuck KH, Mont L, Ng GA, Szumowski L, Themistoclakis S, van Gelder IC, Vardas P, Wegscheider K, Willems S, Kirchhof P. Corrigendum to: Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial. Europace 2021; 24:564. [PMID: 34897422 PMCID: PMC8982426 DOI: 10.1093/europace/euab277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Sell M, Radicke A, Adema B, Daubmann A, Kilian R, Stiawa M, Busmann M, Winter SM, Lambert M, Wegscheider K, Plass-Christl A, Wiegand-Grefe S. Parents With Mental Illness: Parental Coping Behavior and Its Association With Children's Mental Health. Front Psychiatry 2021; 12:737861. [PMID: 34733189 PMCID: PMC8558365 DOI: 10.3389/fpsyt.2021.737861] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 09/20/2021] [Indexed: 11/13/2022] Open
Abstract
The relevance of coping behavior for the individual's own mental health has been widely investigated. However, research on the association between coping of parents with a mental illness and their children's mental health is scarce. In the current study, we address the role of several parental coping strategies and their relation to child psychological symptoms. As part of the German randomized controlled multicenter study CHIMPS (children of mentally ill parents), parents with mental illness completed questionnaires on illness-related coping and child mental health symptoms. Children's diagnoses of a mental disorder were assessed with diagnostic interviews. The sample comprised n = 195 parents with mental illness and n = 290 children and adolescents aged 4-18 years. We conducted mixed models to investigate the associations of parental coping strategies with internalizing and externalizing symptoms as well as the diagnosis of a mental disorder in children controlling for sociodemographic factors and parental symptom severity. Parental coping characterized by religiosity and quest for meaning was significantly associated with fewer mental health symptoms and lower odds of a mental disorder in children, whereas a depressed processing style was related to increased internalizing problems in the children. Coping behavior in parents with mental illness is a relevant factor for the mental health of their children and should be considered in preventive interventions.
Collapse
Affiliation(s)
- Marlit Sell
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Alina Radicke
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Bonnie Adema
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Reinhold Kilian
- Department of Psychiatry II, Ulm University at Bezirkskrankenhaus Guenzburg, Günzburg, Germany
| | - Maja Stiawa
- Department of Psychiatry II, Ulm University at Bezirkskrankenhaus Guenzburg, Günzburg, Germany
| | - Mareike Busmann
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Sibylle M. Winter
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Campus Virchow-Klinikum, Berlin, Germany
| | - Martin Lambert
- Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Angela Plass-Christl
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Department of Child and Adolescent Psychiatry, Evangelical Hospital Hamburg Alsterdorf, Hamburg, Germany
| | - Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
32
|
Sell M, Barkmann C, Adema B, Daubmann A, Kilian R, Stiawa M, Busmann M, Winter SM, Lambert M, Wegscheider K, Wiegand-Grefe S. Associations of Family Functioning and Social Support With Psychopathology in Children of Mentally Ill Parents: Multilevel Analyses From Different Rating Perspectives. Front Psychol 2021; 12:705400. [PMID: 34594270 PMCID: PMC8476746 DOI: 10.3389/fpsyg.2021.705400] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 08/16/2021] [Indexed: 11/13/2022] Open
Abstract
Offspring of mentally ill parents is at heightened risk for psychological symptoms. The identification of environmental factors that predict their mental health is crucial for the development of preventive and therapeutic measures. In the current study, we addressed the combined role of family functioning and social support by taking mentally ill patients’, their partners’, and children’s perspectives into account. The cross-sectional sample included n=195 families (195 patients, 127 partners, and 295 children). Family members completed questionnaires related to family functioning, social support as well as parental and child psychopathology. We conducted multilevel analyses to investigate the associations with internalizing and externalizing problems in children. Family functioning and social support were significantly associated with child internalizing and externalizing problems. However, results varied depending on the rating perspective. We found significant interaction effects of family functioning and social support on child psychopathology. The findings point to the importance of family functioning and social support as potential targets for interventions. Findings should be replicated in future longitudinal studies.
Collapse
Affiliation(s)
- Marlit Sell
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Claus Barkmann
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Bonnie Adema
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Reinhold Kilian
- Department of Psychiatry and Psychotherapy II, Ulm University, Ulm, Germany
| | - Maja Stiawa
- Department of Psychiatry and Psychotherapy II, Ulm University, Ulm, Germany
| | - Mareike Busmann
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Sibylle M Winter
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Campus Virchow-Klinikum, Berlin, Germany
| | - Martin Lambert
- Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
33
|
Engelbertz C, Pinnschmidt HO, Freisinger E, Reinecke H, Schmitz B, Fobker M, Schmieder RE, Wegscheider K, Breithardt G, Pavenstädt H, Brand E. Sex-specific differences and long-term outcome of patients with coronary artery disease and chronic kidney disease: the Coronary Artery Disease and Renal Failure (CAD-REF) Registry. Clin Res Cardiol 2021; 110:1625-1636. [PMID: 34036426 PMCID: PMC8484247 DOI: 10.1007/s00392-021-01864-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 04/21/2021] [Indexed: 10/26/2022]
Abstract
BACKGROUND Cardiovascular morbidity and mortality are closely linked to chronic kidney disease (CKD). Sex-specific long-term outcome data of patients with coronary artery disease (CAD) and CKD are scarce. METHODS In the prospective observational multicenter Coronary Artery Disease and REnal Failure (CAD-REF) Registry, 773 (23.1%) women and 2,579 (76.9%) men with angiographically documented CAD and different stages of CKD were consecutively enrolled and followed for up to 8 years. Long-term outcome was evaluated using survival analysis and multivariable Cox-regression models. RESULTS At enrollment, women were significantly older than men, and suffered from more comorbidities like CKD, hypertension, diabetes mellitus, and multivessel coronary disease. Regarding long-term mortality, no sex-specific differences were observed (Kaplan-Meier survival estimates: 69% in women vs. 69% in men, plog-rank = 0.7). Survival rates decreased from 89% for patients without CKD at enrollment to 72% for patients with CKD stages 1-2 at enrollment and 49% for patients with CKD stages 3-5 at enrollment (plog-rank < 0.001). Cox-regression analysis revealed that sex or multivessel coronary disease were no independent predictors of long-term mortality, while age, CKD stages 3-5, albumin/creatinine ratio, diabetes, valvular heart disease, peripheral artery disease, and left-ventricular ejection fraction were predictors of long-term mortality. CONCLUSIONS Sex differences in CAD patients mainly exist in the cardiovascular risk profile and the extent of CAD. Long-term mortality was not depended on sex or multivessel disease. More attention should be given to treatment of comorbidities such as CKD and peripheral artery disease being independent predictors of death. Clinical Trail Registration ClinicalTrials.gov Identifier: NCT00679419.
Collapse
Affiliation(s)
- Christiane Engelbertz
- Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Cardiol, Muenster, Germany
| | - Hans O Pinnschmidt
- Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Eva Freisinger
- Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Cardiol, Muenster, Germany
| | - Holger Reinecke
- Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Cardiol, Muenster, Germany
| | - Boris Schmitz
- Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Muenster, Muenster, Germany
| | - Manfred Fobker
- Center of Laboratory Medicine, University Hospital Muenster, Muenster, Germany
| | - Roland E Schmieder
- Department of Nephrology and Hypertension, University of Erlangen-Nuernberg, Erlangen, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Günter Breithardt
- Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Cardiol, Muenster, Germany
| | - Hermann Pavenstädt
- Department of Nephrology, Hypertension, and Rheumatology, University Hospital Muenster, Muenster, Germany
| | - Eva Brand
- Department of Nephrology, Hypertension, and Rheumatology, University Hospital Muenster, Muenster, Germany.
- Allg. Innere Medizin sowie Nieren- und Hochdruckkrankheiten und Rheumatologie, Medizinische Klinik D, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Germany.
| |
Collapse
|
34
|
Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Elvan A, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Kuck KH, Mont L, Ng AA, Szumowski L, Themistoclakis S, van Gelder IC, Vardas P, Wegscheider K, Willems S, Kirchhof P. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. Europace 2021; 24:552-564. [PMID: 34473249 PMCID: PMC8982435 DOI: 10.1093/europace/euab200] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Indexed: 11/20/2022] Open
Abstract
Aims Treatment patterns were compared between randomized groups in EAST-AFNET 4 to assess
whether differences in anticoagulation, therapy of concomitant diseases, or intensity of
care can explain the clinical benefit achieved with early rhythm control in EAST-AFNET
4. Methods and results Cardiovascular treatment patterns and number of visits were compared between randomized
groups in EAST-AFNET 4. Oral anticoagulation was used in >90% of patients during
follow-up without differences between randomized groups. There were no differences in
treatment of concomitant conditions between groups. The type of rhythm control varied by
country and centre. Over time, antiarrhythmic drugs were given to 1171/1395 (84%)
patients in early therapy, and to 202/1394 (14%) in usual care. Atrial fibrillation (AF)
ablation was performed in 340/1395 (24%) patients randomized to early therapy, and in
168/1394 (12%) patients randomized to usual care. 97% of rhythm control therapies were
within class I and class III recommendations of AF guidelines. Patients randomized to
early therapy transmitted 297 166 telemetric electrocardiograms (ECGs) to a core lab. In
total, 97 978 abnormal ECGs were sent to study sites. The resulting difference between
study visits was low (0.06 visits/patient/year), with slightly more visits in early
therapy (usual care 0.39 visits/patient/year; early rhythm control 0.45
visits/patient/year, P < 0.001), mainly due to visits for
symptomatic AF recurrences or recurrent AF on telemetric ECGs. Conclusion The clinical benefit of early, systematic rhythm control therapy was achieved using
variable treatment patterns of antiarrhythmic drugs and AF ablation, applied within
guideline recommendations.
Collapse
Affiliation(s)
- Andreas Metzner
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.,German Center of Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Axel Brandes
- Department of Cardiology, Odense University Hospital, Odense, Denmark.,Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - Günter Breithardt
- Atrial Fibrillation Network (AFNET), Münster, Germany.,Department of Cardiology II (Electrophysiology), University Hospital Münster, Münster, Germany
| | - A John Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK
| | - Harry J G M Crijns
- Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht, Netherlands
| | - Lars Eckardt
- Atrial Fibrillation Network (AFNET), Münster, Germany.,Department of Cardiology II (Electrophysiology), University Hospital Münster, Münster, Germany
| | - Arif Elvan
- Isala Hospital and Diagram Research, Zwolle, The Netherlands
| | - Andreas Goette
- Atrial Fibrillation Network (AFNET), Münster, Germany.,St. Vincenz Hospital, Paderborn, Germany.,Working Group of Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, Germany
| | - Laurent M Haegeli
- University Hospital Zurich, Zurich, Switzerland.,Division of Cardiology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland
| | - Hein Heidbuchel
- University Hospital Antwerp and Antwerp University, Antwerp, Belgium
| | - Josef Kautzner
- Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Karl-Heinz Kuck
- German Center of Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany.,Atrial Fibrillation Network (AFNET), Münster, Germany.,LANS Cardio, Hamburg, Germany
| | - Luis Mont
- University of Barcelona and Institut de Recerca Biomèdica, August Pi-Sunyer, Barcelona, Spain.,Centro Investigación Biomedica en Red Cardiovascular, Madrid, Spain
| | - A Andre Ng
- Department of Cardiovascular Sciences, University of Leicester, National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
| | - Lukasz Szumowski
- Arrhythmia Center of the National Institute of Cardiology, Medical Division of Cardinal Stefan Wyszynski University in Warsaw, Warsaw, Poland
| | | | - Isabelle C van Gelder
- University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Panos Vardas
- Heart Sector, Hygeia Hospitals Group, Athens, Greece
| | - Karl Wegscheider
- German Center of Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany.,Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.,Atrial Fibrillation Network (AFNET), Münster, Germany
| | - Stephan Willems
- German Center of Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany.,Atrial Fibrillation Network (AFNET), Münster, Germany.,Department of Cardiology, Asklepios Klinik St. Georg (S.W.), Hamburg, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.,German Center of Cardiovascular Research, Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany.,Atrial Fibrillation Network (AFNET), Münster, Germany.,Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
35
|
Salzwedel A, Koran I, Langheim E, Schlitt A, Nothroff J, Wegscheider K, Völler H. Einfluss patientenberichteter Parameter auf die Rückkehr zur Arbeit und die Lebensqualität nach kardiologischer Rehabilitation: Ergebnisse des multizentrischen Registers OutCaRe. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- A Salzwedel
- Universität Potsdam, Rehabilitationswissenschaften
| | | | | | | | | | - K Wegscheider
- Universitätsklinikum Hamburg-Eppendorf, Institut für Medizinische Biometrie und Epidemiologie
| | | |
Collapse
|
36
|
Becher H, Bönisch S, Wegscheider K. Reduction of Mobility During the COVID-19 Pandemic in Germany According to Age, Sex, and Federal State. Dtsch Arztebl Int 2021; 118:536-537. [PMID: 34612192 PMCID: PMC8503955 DOI: 10.3238/arztebl.m2021.0293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 05/12/2021] [Accepted: 07/08/2021] [Indexed: 11/27/2022]
Affiliation(s)
- Heiko Becher
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf UKE
| | - Sebastian Bönisch
- GIM Gesellschaft für Innovative Marktforschung mbH, Heidelberg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf UKE
| |
Collapse
|
37
|
Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Elvan A, Goette A, Gulizia M, Haegeli L, Heidbuchel H, Kuck KH, Ng A, Szumowski L, van Gelder I, Wegscheider K, Kirchhof P. Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure. Circulation 2021; 144:845-858. [PMID: 34328366 PMCID: PMC8456351 DOI: 10.1161/circulationaha.121.056323] [Citation(s) in RCA: 96] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Supplemental Digital Content is available in the text. Even on optimal therapy, many patients with heart failure and atrial fibrillation experience cardiovascular complications. Additional treatments are needed to reduce these events, especially in patients with heart failure and preserved left ventricular ejection fraction.
Collapse
Affiliation(s)
- Andreas Rillig
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany
| | - Christina Magnussen
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany
| | - Ann-Kathrin Ozga
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany
| | - Anna Suling
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany
| | - Axel Brandes
- Department of Cardiology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - Günter Breithardt
- Atrial Fibrillation Network (AFNET), Münster, Germany; Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany
| | - A John Camm
- Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's University of London, UK
| | - Harry J G M Crijns
- Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Netherlands
| | - Lars Eckardt
- Atrial Fibrillation Network (AFNET), Münster, Germany; Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany
| | - Arif Elvan
- Isala Hospital and Diagram Research, Zwolle, The Netherlands
| | - Andreas Goette
- Atrial Fibrillation Network (AFNET), Münster, Germany; St. Vincenz Hospital, Paderborn, Germany; Working Group of Molecular Electrophysiology, University Hospital Magdeburg, Germany
| | | | - Laurent Haegeli
- University Hospital Zurich, Zurich, Switzerland; Division of Cardiology, Medical University Department, Kantonsspital Aarau, Switzerland
| | - Hein Heidbuchel
- University Hospital Antwerp and Antwerp University, Antwerp, Belgium
| | - Karl-Heinz Kuck
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany; Atrial Fibrillation Network (AFNET), Münster, Germany; LANS Cardio, Hamburg, Germany
| | - Andre Ng
- Department of Cardiovascular Sciences, University of Leicester, National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
| | - Lukasz Szumowski
- Arrhythmia Center of the National Institute of Cardiology; Medical Division of Cardinal Stefan Wyszynski University in Warsaw, Warsaw, Poland
| | - Isabelle van Gelder
- University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Karl Wegscheider
- German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Germany; Atrial Fibrillation Network (AFNET), Münster, Germany
| | - Paulus Kirchhof
- Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Germany; German Center for Cardiovascular Research, Partner Site Hamburg/Luebeck/Kiel, Germany; Atrial Fibrillation Network (AFNET), Münster, Germany; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| |
Collapse
|
38
|
Sikorski F, König HH, Wegscheider K, Zapf A, Löwe B, Kohlmann S. The efficacy of automated feedback after internet-based depression screening: Study protocol of the German, three-armed, randomised controlled trial DISCOVER. Internet Interv 2021; 25:100435. [PMID: 34401394 PMCID: PMC8350593 DOI: 10.1016/j.invent.2021.100435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 07/16/2021] [Accepted: 07/16/2021] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Depression is one of the most disabling disorders worldwide, yet it often remains undetected. One promising approach to address both early detection and disease burden is depression screening followed by direct feedback to patients. Evidence suggests that individuals often seek information regarding mental health on the internet. Thus, internet-based screening with automated feedback has great potential to address individuals with undetected depression. OBJECTIVES To determine whether automated feedback after internet-based depression screening reduces depression severity as compared to no feedback. METHODS The internet-based, observer-blinded DISCOVER RCT aims to recruit a total of 1074 individuals. Participants will be screened for depression using the Patient Health Questionnaire (PHQ-9). In case of a positive screening result (PHQ-9 ≥ 10), participants with undetected depression will be randomised into one of three balanced study arms to receive either (a) no feedback (control arm), (b) standard feedback, or (c) tailored feedback on their screening result. The tailored feedback version will be adapted to participants' characteristics, i.e. symptom profile, preferences, and demographic characteristics. The primary hypothesis is that feedback reduces depression severity six months after screening compared to no feedback. The secondary hypothesis is that tailored feedback is more efficacious compared to standard feedback. Further outcomes are depression care, help-seeking behaviour, health-related quality of life, anxiety, somatic symptom severity, intervention acceptance, illness beliefs, adverse events, and a health economic evaluation. Follow-ups will be conducted one month and six months after screening by self-report questionnaires and clinical interviews. According to a statistical analysis plan, the primary outcome will be analysed on an intention-to-treat basis applying multilevel modelling. DISCUSSION The results of the DISCOVER RCT will inform about how automated feedback after internet-based screening could improve early detection and resolution of depression. Ways of dissemination and how the trial can contribute to an understanding of help-seeking behaviour processes will be discussed. If the results show that automated feedback after internet-based depression screening can reduce depression severity, the intervention could be easily implemented and might substantially reduce the disease burden of individuals with undetected depression. ETHICAL APPROVAL The study is approved by the Ethics Committee of the Hamburg Medical Association. TRIAL REGISTRATION The trial was registered at ClinicalTrials.gov in November 2020 (identifier: NCT04633096).
Collapse
Affiliation(s)
- Franziska Sikorski
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
- Corresponding author at: Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
| | - Hans-Helmut König
- Department of Health Economics and Health Services Research, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Antonia Zapf
- Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Bernd Löwe
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| | - Sebastian Kohlmann
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
39
|
Nabauer M, Oeff M, Gerth A, Wegscheider K, Buchholz A, Haeusler KG, Hanrath P, Meinertz T, Ravens U, Sprenger C, Tebbe U, Vettorazzi E, Kirchhof P, Breithardt G, Steinbeck G. Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). Europace 2021; 23:1903-1912. [PMID: 34136917 DOI: 10.1093/europace/euab113] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Accepted: 04/15/2021] [Indexed: 11/13/2022] Open
Abstract
AIMS Atrial fibrillation (AF) is associated with a high risk of cardiovascular and non-cardiovascular death, even on anticoagulation. It is controversial, which conditions-including concomitant diseases and AF itself-contribute to this mortality. To further clarify these questions, major determinants of long-term mortality and their contribution to death were quantified in an unselected cohort of AF patients. METHODS AND RESULTS We established a large nationwide registry comprising 8833 AF-patients with a median follow-up of 6.5 years (45 345 patient-years) and central adjudication of adverse events. Baseline characteristics of the patients were evaluated as predictors of mortality using Cox regression and C-indices for determination of predictive power. Annualized mortality was highest in the first year (6.2%) and remained high thereafter (5.2% in men and 5.5% in women). Thirty-eight percent of all deaths were cardiovascular, mainly due to heart failure or sudden death. Sex-specific age was the strongest predictor of mortality, followed by concomitant cardiovascular and non-cardiovascular conditions. These factors accounted for 25% of the total mortality beyond age and sex and for 84% of the mortality differences between AF types. Thus, the electrical phenotype of the disease at baseline contributed only marginally to prediction of mortality. CONCLUSION Mortality is high in AF patients and arises primarily from heart failure, peripheral artery disease, chronic obstructive lung disease, chronic kidney disease, and diabetes mellitus, which, therefore, should be targeted to lower mortality. Parameters related to the electrical manifestation of AF did not have an independent impact on long-term mortality in our representative cohort.
Collapse
Affiliation(s)
- Michael Nabauer
- Medical Clinic I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany
| | - Michael Oeff
- Department of Medicine I, Brandenburg Municipal Hospital, Brandenburg, Germany
| | - Andrea Gerth
- Medical Clinic I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anika Buchholz
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Peter Hanrath
- Medical Clinic I, University Hospital RWTH, Aachen, Germany
| | - Thomas Meinertz
- Department of Cardiology/Angiology, University Hospital Eppendorf, Hamburg, Germany
| | - Ursula Ravens
- Institute for Experimental Cardiovascular Medicine, University Heart Center, University of Freiburg, Freiburg, Germany.,Institute of Physiology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany
| | - Claudia Sprenger
- Department of Medicine I, Brandenburg Municipal Hospital, Brandenburg, Germany
| | - Ulrich Tebbe
- Department of Cardiology, Hospital Detmold, Detmold, Germany
| | - Eik Vettorazzi
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Paulus Kirchhof
- Department of Cardiology/Angiology, University Hospital Eppendorf, Hamburg, Germany
| | - Günter Breithardt
- Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
| | - Gerhard Steinbeck
- Medical Clinic I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany
| |
Collapse
|
40
|
Wollny A, Löffler C, Drewelow E, Altiner A, Helbig C, Daubmann A, Wegscheider K, Löscher S, Pentzek M, Wilm S, Feldmeier G, Santos S. Shared decision making and patient-centeredness for patients with poorly controlled type 2 diabetes mellitus in primary care-results of the cluster-randomised controlled DEBATE trial. BMC Fam Pract 2021; 22:93. [PMID: 33992088 PMCID: PMC8126132 DOI: 10.1186/s12875-021-01436-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 04/12/2021] [Indexed: 11/23/2022]
Abstract
Background We investigate whether an educational intervention of GPs increases patient-centeredness and perceived shared decision making in the treatment of patients with poorly controlled type 2 diabetes mellitus? Methods We performed a cluster-randomized controlled trial in German primary care. Patients with type 2 diabetes mellitus defined as HbA1c levels ≥ 8.0% (64 mmol/mol) at the time of recruitment (n = 833) from general practitioners (n = 108) were included. Outcome measures included subjective shared decision making (SDM-Q-9; scale from 0 to 45 (high)) and patient-centeredness (PACIC-D; scale from 1 to 5 (high)) as secondary outcomes. Data collection was performed before intervention (baseline, T0), at 6 months (T1), at 12 months (T2), at 18 months (T3), and at 24 months (T4) after baseline. Results Subjective shared decision making decreased in both groups during the course of the study (intervention group: -3.17 between T0 and T4 (95% CI: -4.66, -1.69; p < 0.0001) control group: -2.80 (95% CI: -4.30, -1.30; p = 0.0003)). There were no significant differences between the two groups (-0.37; 95% CI: -2.20, 1.45; p = 0.6847). The intervention's impact on patient-centeredness was minor. Values increased in both groups, but the increase was not statistically significant, nor was the difference between the groups. Conclusions The intervention did not increase patient perceived subjective shared decision making and patient-centeredness in the intervention group as compared to the control group. Effects in both groups might be partially attributed to the Hawthorne-effect. Future trials should focus on patient-based intervention elements to investigate effects on shared decision making and patient-centeredness. Trial registration The trial was registered on March 10th, 2011 at ISRCTN registry under the reference ISRCTN70713571.
Collapse
Affiliation(s)
- Anja Wollny
- Institute of General Practice, Rostock University Medical Centre, Doberaner Str. 142, 18057, Rostock, Germany
| | - Christin Löffler
- Institute of General Practice, Rostock University Medical Centre, Doberaner Str. 142, 18057, Rostock, Germany.
| | - Eva Drewelow
- Institute of General Practice, Rostock University Medical Centre, Doberaner Str. 142, 18057, Rostock, Germany
| | - Attila Altiner
- Institute of General Practice, Rostock University Medical Centre, Doberaner Str. 142, 18057, Rostock, Germany
| | - Christian Helbig
- Institute of General Practice, Rostock University Medical Centre, Doberaner Str. 142, 18057, Rostock, Germany
| | - Anne Daubmann
- Institute of Medical Biometry and Epidemiology, Medical Centre Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, Medical Centre Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Susanne Löscher
- Institute of General Practice (Ifam), Medical Faculty, Centre for Health & Society (Chs), Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Michael Pentzek
- Institute of General Practice (Ifam), Medical Faculty, Centre for Health & Society (Chs), Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Stefan Wilm
- Institute of General Practice (Ifam), Medical Faculty, Centre for Health & Society (Chs), Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Gregor Feldmeier
- Institute of General Practice, Rostock University Medical Centre, Doberaner Str. 142, 18057, Rostock, Germany
| | - Sara Santos
- Institute of General Practice (Ifam), Medical Faculty, Centre for Health & Society (Chs), Heinrich-Heine University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
| |
Collapse
|
41
|
Clemmensen P, Schrage B, Zeymer U, Thiele H, Wegscheider K. Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trials-lessons from CULPRIT-SHOCK. Trials 2021; 22:197. [PMID: 33685472 PMCID: PMC7941876 DOI: 10.1186/s13063-021-05129-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Accepted: 02/13/2021] [Indexed: 11/17/2022] Open
Affiliation(s)
- Peter Clemmensen
- University Heart and Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - Benedikt Schrage
- University Heart and Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany.
| | - Uwe Zeymer
- Klinikum Ludwigshafen, Ludwigshafen am Rhein, Germany
| | - Holger Thiele
- Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany
| | | |
Collapse
|
42
|
Brachmann J, Sohns C, Andresen D, Siebels J, Sehner S, Boersma L, Merkely B, Pokushalov E, Sanders P, Schunkert H, Bänsch D, Dagher L, Zhao Y, Mahnkopf C, Wegscheider K, Marrouche NF. Atrial Fibrillation Burden and Clinical Outcomes in Heart Failure: The CASTLE-AF Trial. JACC Clin Electrophysiol 2021; 7:594-603. [PMID: 33640355 DOI: 10.1016/j.jacep.2020.11.021] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 11/06/2020] [Accepted: 11/08/2020] [Indexed: 02/03/2023]
Abstract
OBJECTIVES This subanalysis of the CASTLE-AF (Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF) trial aimed to address the association between atrial fibrillation (AF) recurrence, AF burden, and hard clinical outcomes in heart failure (HF) patients with AF. BACKGROUND The CASTLE-AF trial demonstrated the benefit of CA compared to pharmacological treatment in decreasing mortality and CV hospitalizations in patients with AF and HFrEF. However, the impact of AF recurrence and AF burden after ablation on long-term treatment benefit remains unknown. METHODS The CASTLE-AF protocol randomized 363 patients with coexisting HF and AF in a multicenter prospective controlled fashion to catheter ablation (n = 179) versus pharmacological therapy (n = 184). Two hundred eighty patients were included in this subanalysis (as-treated), 128 of them underwent ablation and 152 received pharmacological treatment. All patients had implanted dual chamber or biventricular implantable defibrillators with activated home monitoring capabilities. The individual AF burden was calculated as the percentage of the atrial arrhythmia time per day. RESULTS AF burden at baseline was not predictive of the primary endpoint (p = 0.473) or all-cause mortality (p = 0.446). AF recurrence (defined as any episode >30 s) did not show any relationship with the primary endpoints of mortality and occurrence of HF, irrespective of the treatment arm. An AF burden below 50% after 6 months of catheter ablation, was associated with a significant decrease in primary composite outcome (hazard ratio [HR]: 0.33; 95% confidence interval [CI]: 0.15 to 0.71; p = 0.014) and all-cause mortality (HR: 0.23; 95% CI: 0.07 to 0.71; p = 0.031). The risk of the primary endpoint or mortality was directly related to a low (<50%) or high (≥50%) AF burden at 6 months post-ablation. CONCLUSIONS AF burden at 6 months was predictive of hard clinical outcomes in HF patients with AF. The first recurrent atrial tachyarrhythmia episode >30 s after ablation was not associated with improvement in mortality and hospitalization for HF. (Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF [CASTLE-AF]; NCT00643188).
Collapse
Affiliation(s)
| | - Christian Sohns
- Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
| | | | | | - Susanne Sehner
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Luca Boersma
- Department of Cardiology, Antonius Ziekenhuis Nieuwegein, Nieuwegein, the Netherlands
| | - Béla Merkely
- Department of Cardiology, Semmelweis Medical University, Budapest, Hungary
| | - Evgeny Pokushalov
- State Research Institute of Circulation Pathology, Novosibirsk, Russia
| | - Prashanthan Sanders
- Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
| | - Heribert Schunkert
- Department of Cardiology, Deutsches Herzzentrum München, Munich, Germany
| | - Dietmar Bänsch
- Clinic for Electrophysiology, KMG Klinikum, Güstrow, Germany
| | - Lilas Dagher
- Cardiac Electrophysiology, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Yan Zhao
- Cardiac Electrophysiology, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | | | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Nassir F Marrouche
- Cardiac Electrophysiology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
| |
Collapse
|
43
|
Waldmann T, Stiawa M, Dinc Ü, Saglam G, Busmann M, Daubmann A, Adema B, Wegscheider K, Wiegand-Grefe S, Kilian R. Costs of health and social services use in children of parents with mental illness. Child Adolesc Psychiatry Ment Health 2021; 15:10. [PMID: 33610177 PMCID: PMC7897390 DOI: 10.1186/s13034-021-00360-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 02/03/2021] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Children of parents with mental illness have a higher risk of developing mental health problems when compared with the general population. Therefore, families with parents with mental illness are a suitable target group for selective prevention. In order to plan and evaluate the health economic consequences of preventive interventions for this target group, data on the societal costs related to parenthood under the condition of mental disorders are needed. To date, within Germany there has been a lack of research evaluating the costs of mental health treatment and use of social services by children and adolescents with parents with mental illness. METHODS As part of a multicentre randomised controlled trial, use and costs of health and social services were assessed for a sample of 332 children and adolescents with parents with mental illness in six regions of Germany. Service use at baseline was assessed by the German version of the Children and Adolescent Mental Health Service Receipt Inventory. Costs were calculated for 12 months based on diagnosis and service user status and described separately. Cost drivers were identified by means of a two-part regression model. RESULTS Total mean costs for 12 months for the total sample amount of € 3736.35 (95% CI: € 2816.84-4813.83) per person. Children with a psychiatric diagnosis generated a total of € 5691.93 (95% CI: € 4146.27-7451.38) of costs per person, compared to € 1245.01 (95% CI: € 657.44-1871.49) for children without a psychiatric diagnosis. The logit part indicates significant odds ratios for individual functioning and diagnosis of the child as well as for family functioning. The linear part reveals that increasing individual functioning in the child is related to decreasing costs. CONCLUSIONS Children of families with parents with mental illness use a broad spectrum of mental health care, school-based support and youth welfare services even if they are not yet diagnosed as having a mental disorder. Further research should examine whether these institutions are sufficiently qualified and interlinked to meet the support needs of this vulnerable group. Trial registration The study was registered at the 07/10/2014 before the start of data collection (04/11/2014) at the German clinical trials register (Deutsches Register Klinischer Studien, DRKS, nr: DRKS00006806, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00006806 ).
Collapse
Affiliation(s)
- Tamara Waldmann
- Department of Psychiatry and Psychotherapy II, University of Ulm and BKH Günzburg, Lindenallee 2, 89312, Günzburg, Germany.
| | - Maja Stiawa
- grid.6582.90000 0004 1936 9748Department of Psychiatry and Psychotherapy II, University of Ulm and BKH Günzburg, Lindenallee 2, 89312 Günzburg, Germany
| | - Ümügülsüm Dinc
- grid.6582.90000 0004 1936 9748Department of Psychiatry and Psychotherapy II, University of Ulm and BKH Günzburg, Lindenallee 2, 89312 Günzburg, Germany
| | - Gülsah Saglam
- grid.6582.90000 0004 1936 9748Department of Psychiatry and Psychotherapy II, University of Ulm and BKH Günzburg, Lindenallee 2, 89312 Günzburg, Germany
| | - Mareike Busmann
- grid.13648.380000 0001 2180 3484Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Anne Daubmann
- grid.13648.380000 0001 2180 3484Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Bonnie Adema
- grid.13648.380000 0001 2180 3484Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Karl Wegscheider
- grid.13648.380000 0001 2180 3484Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Silke Wiegand-Grefe
- grid.13648.380000 0001 2180 3484Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
| | - Reinhold Kilian
- grid.6582.90000 0004 1936 9748Department of Psychiatry and Psychotherapy II, University of Ulm and BKH Günzburg, Lindenallee 2, 89312 Günzburg, Germany
| |
Collapse
|
44
|
Albert J, Lezius S, Störk S, Morbach C, Güder G, Frantz S, Wegscheider K, Ertl G, Angermann CE. Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes. J Am Heart Assoc 2021; 10:e017822. [PMID: 33496189 PMCID: PMC7955416 DOI: 10.1161/jaha.120.017822] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Background Prospective longitudinal follow‐up of left ventricular ejection fraction (LVEF) trajectories after acute cardiac decompensation of heart failure is lacking. We investigated changes in LVEF and covariates at 6‐months' follow‐up in patients with a predischarge LVEF ≤40%, and determined predictors and prognostic implications of LVEF changes through 18‐months' follow‐up. Methods and Results Interdisciplinary Network Heart Failure program participants (n=633) were categorized into subgroups based on LVEF at 6‐months' follow‐up: normalized LVEF (>50%; heart failure with normalized ejection fraction, n=147); midrange LVEF (41%–50%; heart failure with midrange ejection fraction, n=195), or persistently reduced LVEF (≤40%; heart failure with persistently reduced LVEF , n=291). All received guideline‐directed medical therapies. At 6‐months' follow‐up, compared with patients with heart failure with persistently reduced LVEF, heart failure with normalized LVEF or heart failure with midrange LVEF subgroups showed greater reductions in LV end‐diastolic/end‐systolic diameters (both P<0.001), and left atrial systolic diameter (P=0.002), more increased septal/posterior end‐diastolic wall‐thickness (both P<0.001), and significantly greater improvement in diastolic function, biomarkers, symptoms, and health status. Heart failure duration <1 year, female sex, higher predischarge blood pressure, and baseline LVEF were independent predictors of LVEF improvement. Mortality and event‐free survival rates were lower in patients with heart failure with normalized LVEF (P=0.002). Overall, LVEF increased further at 18‐months' follow‐up (P<0.001), while LV end‐diastolic diameter decreased (P=0.048). However, LVEF worsened (P=0.002) and LV end‐diastolic diameter increased (P=0.047) in patients with heart failure with normalized LVEF hospitalized between 6‐months' follow‐up and 18‐months' follow‐up. Conclusions Six‐month survivors of acute cardiac decompensation for systolic heart failure showed variable LVEF trajectories, with >50% showing improvements by ≥1 LVEF category. LVEF changes correlated with various parameters, suggesting multilevel reverse remodeling, were predictable from several baseline characteristics, and were associated with clinical outcomes at 18‐months' follow‐up. Repeat hospitalizations were associated with attenuation of reverse remodeling. Registration URL: https://www.controlled‐trials.com; Unique identifier: ISRCTN23325295.
Collapse
Affiliation(s)
- Judith Albert
- Department of Internal Medicine I Cardiology University Hospital Würzburg Würzburg Germany.,Comprehensive Heart Failure Centre University and University Hospital Würzburg Germany
| | - Susanne Lezius
- Medical Center Hamburg-EppendorfInstitute of Medical Biometry and Epidemiology Hamburg Germany
| | - Stefan Störk
- Department of Internal Medicine I Cardiology University Hospital Würzburg Würzburg Germany.,Comprehensive Heart Failure Centre University and University Hospital Würzburg Germany
| | - Caroline Morbach
- Department of Internal Medicine I Cardiology University Hospital Würzburg Würzburg Germany.,Comprehensive Heart Failure Centre University and University Hospital Würzburg Germany
| | - Gülmisal Güder
- Department of Internal Medicine I Cardiology University Hospital Würzburg Würzburg Germany.,Comprehensive Heart Failure Centre University and University Hospital Würzburg Germany
| | - Stefan Frantz
- Department of Internal Medicine I Cardiology University Hospital Würzburg Würzburg Germany.,Comprehensive Heart Failure Centre University and University Hospital Würzburg Germany
| | - Karl Wegscheider
- Medical Center Hamburg-EppendorfInstitute of Medical Biometry and Epidemiology Hamburg Germany
| | - Georg Ertl
- Comprehensive Heart Failure Centre University and University Hospital Würzburg Germany
| | | |
Collapse
|
45
|
Wiegand-Grefe S, Filter B, Busmann M, Kilian R, Kronmüller KT, Lambert M, Norra C, von Klitzing K, Albermann K, Winter SM, Daubmann A, Wegscheider K, Plass-Christl A. Evaluation of a Family-Based Intervention Program for Children of Mentally Ill Parents: Study Protocol for a Randomized Controlled Multicenter Trial. Front Psychiatry 2021; 11:561790. [PMID: 33551858 PMCID: PMC7854699 DOI: 10.3389/fpsyt.2020.561790] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 12/18/2020] [Indexed: 01/06/2023] Open
Abstract
Background: Children of mentally ill parents have a three to seven times higher risk of developing mental disorders compared to the general population. For this high-risk group, specialized prevention and intervention programs have already been developed. However, there has been insufficient sytematic evaluation to date. Moreover, effectiveness and the cost-effectiveness data of the respective programs until today is very scarce and at the same time constitutes the pre-condition for the program's implementation into regular health care. Methods: The study consists of a two-group randomized controlled multicenter trial conducted at seven study sites throughout Germany and Switzerland. Participants are families with mentally ill parents and their children aged from 3 to 19 years. The intervention comprises 6 to 8 semi-structured sessions over a period of about 6 months. Topics discussed in the intervention include parental mental illness, coping, family relations and social support. Families in the control condition will receive treatment as usual. The children's mental health, assessed using the K-SADS-PL by blinded external raters will constitute the primary efficacy outcome. Further outcomes will be assessed from the parents' as well as from the children's perspectives. Participants are investigated at baseline, 6, 12, and 18 months after baseline assessment. In addition to the assessment of various psychosocial outcomes, a comprehensive health-economic evaluation will be performed. Discussion: This paper describes the evaluation of a family-based intervention program for children of mentally ill parents (CHIMPs) in the regular health care system in Germany and Switzerland. A methodically sophisticated study design has been developed to reflect the complexity of the actual health care situation. This trial will contribute to the regular health care for the high-risk group of children of mentally ill parents. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02308462; German Clinical Trials Register: DRKS00006806.
Collapse
Affiliation(s)
- Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Bonnie Filter
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Mareike Busmann
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Reinhold Kilian
- Section of Health Economics and Health Services Research, Department of Psychiatry and Psychotherapy II, Ulm University, Günzburg, Germany
| | - Klaus-Thomas Kronmüller
- Department of General Psychiatry, Landschaftsverband Westfalen-Lippe (LWL) Hospital Gütersloh, Gütersloh, Germany
| | - Martin Lambert
- Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Christine Norra
- Department of General Psychiatry and Psychotherapy, LWL Hospital Paderborn, Paderborn, Germany
| | - Kai von Klitzing
- Department of Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics, University of Leipzig, Leipzig, Germany
| | - Kurt Albermann
- Centre of Social Paediatrics, Cantonal Hospital Winterthur, Winterthur, Switzerland
| | - Sibylle Maria Winter
- Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Angela Plass-Christl
- Department Child and Adolescent Psychiatry, Evangelical Hospital Hamburg Alsterdorf, Hamburg, Germany
| |
Collapse
|
46
|
Radicke A, Barkmann C, Adema B, Daubmann A, Wegscheider K, Wiegand-Grefe S. Children of Parents with a Mental Illness: Predictors of Health-Related Quality of Life and Determinants of Child-Parent Agreement. Int J Environ Res Public Health 2021; 18:ijerph18020379. [PMID: 33418993 PMCID: PMC7825308 DOI: 10.3390/ijerph18020379] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Revised: 12/31/2020] [Accepted: 01/02/2021] [Indexed: 11/16/2022]
Abstract
(1) Background: Health-related quality of life (HRQoL) is frequently reduced in children of parents with a mental illness (COPMI). Child self- and parent proxy-ratings vary with raters’ characteristics and facets of HRQoL. This study aimed at analyzing risk and protective factors associated with HRQoL in COPMI, and at examining the magnitude, direction, and predictors of child–parent agreement. (2) Methods: Analyses were based on baseline data of the German CHIMPS (children of parents with a mental illness) project with n = 134 parents diagnosed with mental illness and n = 198 children and adolescents aged 8 to 18 years. (3) Results: Both children and parents reported significantly lower HRQoL than the reference population, particularly for the child’s physical and psychological well-being. Parents’ proxy-report indicated a lower HRQoL than the children’s self-report. Child and parental psychopathology, social support, and the child’s age significantly predicted HRQoL. Interrater agreement was satisfactory and better for observable aspects like physical well-being and school environment. The child’s gender-identity and mental health significantly predicted child–parent agreement. (4) Conclusions: Parental psychopathology significantly reduces children’s HRQoL. Interventions should promote resilience in children by targeting risk and protective factors. Child–parent agreement emphasizes the need to obtain both self- and proxy-reports, whenever possible.
Collapse
Affiliation(s)
- Alina Radicke
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; (C.B.); (B.A.); (S.W.-G.)
- Correspondence:
| | - Claus Barkmann
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; (C.B.); (B.A.); (S.W.-G.)
| | - Bonnie Adema
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; (C.B.); (B.A.); (S.W.-G.)
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; (A.D.); (K.W.)
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; (A.D.); (K.W.)
| | - Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany; (C.B.); (B.A.); (S.W.-G.)
| |
Collapse
|
47
|
Radicke A, Sell M, Adema B, Daubmann A, Kilian R, Busmann M, Winter SM, Lambert M, Wegscheider K, Wiegand-Grefe S. Risk and Protective Factors Associated With Health-Related Quality of Life of Parents With Mental Illness. Front Psychiatry 2021; 12:779391. [PMID: 34925103 PMCID: PMC8672802 DOI: 10.3389/fpsyt.2021.779391] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Accepted: 11/01/2021] [Indexed: 11/20/2022] Open
Abstract
Purpose: Health-related quality of life (HRQoL) can be reduced in parents with mental illness (mental illness) who face the dual demands of disabling symptoms and their impact on family, social, and occupational life. This study aimed at analyzing the influence of various factors on HRQoL in parents with mental illness. Method: Baseline data of the German randomized controlled multicenter project CHIMPS (children of parents with mental illness) was used for analyses. The final sample consisted of n = 208 parents with mental illness and n = 197 children and adolescents aged 8-18 years. HRQoL was assessed with the EQ-5D. Results: Parents with mental illness reported significantly lower global and specific HRQoL than the German reference population. They were least satisfied with aspects that relate to anxiety and depression followed by usual activities, pain and discomfort. Better global HRQoL was primarily associated with self-reported physical and mental health, as well as adaptive coping behavior. Associations with mobility, self-care, usual activity, pain and discomfort, anxiety and depression were analyzed and discussed. Conclusions: HRQoL in parents with mental illness is reduced. Clinical interventions should focus on the alleviation of mental health symptoms and probably somatic symptoms and promote adaptive coping skills.
Collapse
Affiliation(s)
- Alina Radicke
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marlit Sell
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Bonnie Adema
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Reinhold Kilian
- Department of Psychiatry II, Ulm University at Bezirkskrankenhaus Guenzburg, Guenzburg, Germany
| | - Mareike Busmann
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Sibylle M Winter
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Berlin Institute of Health (BIH) and Charité Medical University of Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - Martin Lambert
- Department of Adult Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Silke Wiegand-Grefe
- Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
48
|
Hoffmann E, Straube F, Wegscheider K, Kuniss M, Andresen D, Wu LQ, Tebbenjohanns J, Noelker G, Tilz RR, Chun JKR, Franke A, Stellbrink C, Garcia-Alberola A, Dorwarth U, Metzner A, Ouarrak T, Brachmann J, Kuck KH, Senges J. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation. Europace 2020; 21:1313-1324. [PMID: 31199860 PMCID: PMC6735953 DOI: 10.1093/europace/euz155] [Citation(s) in RCA: 75] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Accepted: 05/03/2019] [Indexed: 12/17/2022] Open
Abstract
Aims To evaluate the effectiveness and safety of cryoballoon ablation (CBA) compared with radiofrequency ablation (RFA) for symptomatic paroxysmal or drug-refractory persistent atrial fibrillation (AF). Methods and results Prospective cluster cohort study in experienced CBA and RFA centres. Primary endpoint was ‘atrial arrhythmia recurrence’, secondary endpoints were as follows: procedural results, safety, and clinical course. A total of 4189 patients were included: CBA 2329 (55.6%) and RFA 1860 (44.4%). Cryoballoon ablation population was younger, with fewer comorbidities. Procedure time was longer in the RFA group (P = 0.01). Radiation exposure was 2487 (CBA) and 1792 cGycm2 (RFA) (P < 0.001). Follow-up duration was 441 (CBA) and 511 days (RFA) (P < 0.0001). Primary endpoint occurred in 30.7% (CBA) and 39.4% patients (RFA) [adjusted hazard ratio (adjHR) 0.85, 95% confidence interval (CI) 0.70–1.04; P = 0.12). In paroxysmal AF, CBA resulted in a lower risk of recurrence (adjHR 0.80, 95% CI 0.64–0.99; P = 0.047). In persistent AF, the primary outcome was not different between groups. Major adverse cardiovascular and cerebrovascular event rates were 1.0% (CBA) and 2.8% (RFA) (adjHR 0.53, 95% CI 0.26–1.10; P = 0.088). Re-ablations (adjHR 0.46, 95% CI 0.34–0.61; P < 0.0001) and adverse events during follow-up (adjHR 0.64, 95% CI 0.48–0.88; P = 0.005) were less common after CBA. Higher rehospitalization rates with RFA were caused by re-ablations. Conclusions The primary endpoint did not differ between CBA and RFA. Cryoballoon ablation was completed rapidly; the radiation exposure was greater. Rehospitalization due to re-ablations and adverse events during follow-up were observed significantly less frequently after CBA than after RFA. Subgroup analysis suggested a lower risk of recurrence after CBA in paroxysmal AF. Trial Registration ClinicalTrials.gov (NCT01360008), https://clinicaltrials.gov/ct2/show/NCT01360008.
Collapse
Affiliation(s)
- Ellen Hoffmann
- Department of Cardiology and Internal Intensive Care Medicine, Heart Center Munich-Bogenhausen - Munich Municipal Hospital Group, Englschalkinger Str. 77, Munich, Germany
| | - Florian Straube
- Department of Cardiology and Internal Intensive Care Medicine, Heart Center Munich-Bogenhausen - Munich Municipal Hospital Group, Englschalkinger Str. 77, Munich, Germany
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Eppendorf, Hamburg, Germany
| | - Malte Kuniss
- Department of Cardiology, Kerckhoff Clinic, Bad Nauheim, Germany
| | - Dietrich Andresen
- Department of Cardiology at Evangelisches Krankenhaus Hubertus, Paul Gerhardt Diakonie gAG, Berlin, Germany
| | - Li-Qun Wu
- Department of Cardiology, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Jürgen Tebbenjohanns
- HELIOS Klinikum Hildesheim, Medizinische Klinik I - Kardiologie, Hildesheim, Germany
| | - Georg Noelker
- Department of Cardiology, Herz-und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany
| | - Roland Richard Tilz
- Department of Cardiology, Angiology, and Intensive Care Medicine, University Heart Centre Luebeck, University Hospital Schleswig-Holstein, Luebeck, Germany.,Department of Cardiology, Asklepios Clinic St. Georg, Hamburg, Germany
| | | | - Andreas Franke
- Department of Cardiology, KRH Klinikum Siloah-Oststadt-Heidehaus, Hannover, Germany
| | | | - Arcadi Garcia-Alberola
- Department of Cardiology, University Hospital Virgen de la Arrixaca, El-Palmar, Murcia, Spain
| | - Uwe Dorwarth
- Department of Cardiology and Internal Intensive Care Medicine, Heart Center Munich-Bogenhausen - Munich Municipal Hospital Group, Englschalkinger Str. 77, Munich, Germany
| | - Andreas Metzner
- Department of Cardiology, Asklepios Clinic St. Georg, Hamburg, Germany
| | - Taoufik Ouarrak
- Stiftung Institut fuer Herzinfarktforschung, Ludwigshafen, Germany
| | | | - Karl-Heinz Kuck
- Department of Cardiology, Asklepios Clinic St. Georg, Hamburg, Germany
| | - Jochen Senges
- Stiftung Institut fuer Herzinfarktforschung, Ludwigshafen, Germany
| | | |
Collapse
|
49
|
Watzke B, Heddaeus D, Steinmann M, Daubmann A, Wegscheider K, Härter M. Does symptom severity matter in stepped and collaborative care for depression? J Affect Disord 2020; 277:287-295. [PMID: 32854052 DOI: 10.1016/j.jad.2020.07.079] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Revised: 05/22/2020] [Accepted: 07/05/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND We investigated the differential effectiveness of a stepped and collaborative care model (SCM) vs. treatment as usual (TAU) for primary care patients with various depression severity degrees and explored whether subgroups received distinct evidence-based treatments. METHODS Subgroup analyses of a RCT were calculated applying a multiple linear mixed model with the factors 1. group (SCM; TAU), 2. severity ((mild-moderate (MMD); severe depression (SD)) and their interaction, with PHQ-9 as primary outcome. Utilization of treatments was analyzed descriptively. RESULTS For the 737 participating patients (SCM: n = 569; TAU: n = 168), availability of data substantially varies between subgroups at 12-month follow-up ranging between 37% and 70%. ITT-analysis (Last-observation-carried-forward) revealed a significant interaction for group x severity [p = 0.036] and a significant difference between groups in symptom reduction for MMD (-3.9; [95% CI: -5.1 to -2.6, p < 0.001; d = 0.64] but not for SD (-1.6; [95% CI: -3.4 to 0.2, p = 0.093; d = 0.27]. Sensitivity analyses (multiple imputation, completer analysis, pattern mixture model) didn`t confirm the interaction effect and showed significant effects for both severity groups with slightly higher effect sizes for MMD. Differences between SCM and TAU in the percentage of patients utilizing depression-specific treatments are larger for MMD. LIMITATIONS There was a high proportion of missing values among severely depressed patients, especially in SCM. CONCLUSION SCM is effective for both MMD and SD. Utilization patterns might help explain the higher effects for MMD. Various strategies of replacement of missing values lead to slightly divergent results due to selective drop out between severity groups.
Collapse
Affiliation(s)
- Birgit Watzke
- Clinical Psychology and Psychotherapy Research, Institute of Psychology, University of Zurich, Binzmühlestrasse 14/16, CH-8050 Zurich, Switzerland.
| | - Daniela Heddaeus
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
| | - Maya Steinmann
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
| | - Anne Daubmann
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
| | - Karl Wegscheider
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
| | - Martin Härter
- Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
| |
Collapse
|
50
|
Chen Y, Postmus D, Cowie MR, Woehrle H, Wegscheider K, Simonds AK, Boezen M, Somers VK, Teschler H, Eulenburg C. Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine. Eur Respir J 2020; 57:13993003.03206-2020. [PMID: 33243841 DOI: 10.1183/13993003.03206-2020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 11/04/2020] [Indexed: 11/05/2022]
Affiliation(s)
- Yuntao Chen
- Dept of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands
| | - Douwe Postmus
- Dept of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands
| | | | - Holger Woehrle
- ResMed Science Center, ResMed Germany Inc., Martinsried, Germany.,Sleep and Ventilation Center Blaubeuren, Respiratory Center Ulm, Ulm, Germany
| | - Karl Wegscheider
- Dept of Medical Biometry and Epidemiology, University Medical Center Eppendorf, Hamburg, Germany
| | - Anita K Simonds
- Sleep and Ventilation Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Marike Boezen
- Dept of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands
| | | | - Helmut Teschler
- Dept of Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Christine Eulenburg
- Dept of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands
| |
Collapse
|